I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Placebo was defined as any therapy that is used for its nonspecific psychological and physiologic effect but has no specific pharmacologic impact on the condition being treated.\[[@ref1]\] Besides medication therapies, studies have found that the optimal dietary approach as well as physical activity and education are useful to control hyperglycemia in patients with type 2 diabetes (T2DM).\[[@ref2]\] Several reviews reported that increasing physical activity and exercise improved glucose control in people with T2DM, yielding an average reduction of glycosylated hemoglobin (HbA1c) of between 0.4% and 0.6%.\[[@ref3][@ref4][@ref5]\] Hence, the knowledge of placebo effects is important to evaluate the efficacy of a new drug to determine its real effective in glucose control or body weight control. It is also useful for blind trials to evaluate the effect difference between treatment groups and placebo groups. Moreover, in randomized controlled trails (RCTs) or observational studies, it is useful for testing the placebo-corrected efficacy in glucose control even if the control group was an active antidiabetic drug.\[[@ref1][@ref6][@ref7]\]

With the increasing prevalence of T2DM in Asian population and the unmet need for improving glucose control,\[[@ref8][@ref9][@ref10]\] the placebo-controlled RCTs of novel agents have been carried out in both Asian and Caucasian patients with T2DM. It was suggested that the placebo response in clinical trials represents more than just regression to the mean and passage of time;\[[@ref11]\] well-learned and definitely understood placebo effect are likely to be related to better design and execution of diabetes trials in Asian and Caucasian populations.\[[@ref12][@ref13]\]

Due to the lower body mass index (BMI) and other different demographics of Asian patients compared with that of Caucasian patients\[[@ref9][@ref14]\] and the complicate genetic and pharmacogenetic ethnic background\[[@ref15][@ref16]\] or variable response to antidiabetic treatment,\[[@ref17][@ref18][@ref19]\] the placebo effect of glucose control and body weight control between the two ethnicities might be different. The exact placebo effect in T2DM treatment has not been evaluated comprehensively so far, especially in Asian and Caucasian patients. If the trial was done mainly in Caucasian population (\>50%), it would be classified as Caucasian group, if the trial was done mainly in Asian population (\>50%), it would be classified as Asian group.\[[@ref17][@ref18][@ref19]\] Therefore, the aim of this study was to evaluate the placebo effects of antidiabetic therapies in Asian and Caucasian T2DM patients and make comparison between the two ethnicities.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Search strategy {#sec2-1}
---------------

A search using the MEDLINE database, EMBASE, and Cochrane Database was performed, from when recording began to December 2016. The strategy was performed using the following terms in English: sulfonylurea (SU); alpha glucosidase inhibitors (AGIs); metformin (MET); thiazolidinediones (TZD); dipeptidyl peptidase-4 inhibitors (DPP-4i); sodium-glucose cotransporter 2 inhibitors (SGLT2i); glucagon-like peptide-1 receptor analogues (GLP-1RA); type 2 diabetes (T2DM); placebo controlled; and randomized controlled trials. The search was conducted from June 2014 to October 2016. This meta-analysis was registered as CRD42014009373.

Study selection {#sec2-2}
---------------

To evaluate the placebo effects of antidiabetic therapies in T2DM patients, the inclusion criteria were therefore listed as follows: (1) placebo-controlled, randomized trials; (2) included T2DM participants; (3) the study duration ≥12 weeks; (4) the levels of HbA1c changed from baseline were measured in the placebo group; and (5) the ethnicity was reported in the trial.

According to the inclusion criteria, two authors (Nie L, Xu ML) independently screened the studies one by one. If there is any disagreement, a third author (Wang XR) will be consulted. Using the Cochrane instrument, we evaluated the adequacy of randomization, allocation concealment procedures, and blinding.\[[@ref20]\]

Data extraction {#sec2-3}
---------------

The following data were independently extracted using a standardized form. Study titles and authors, study design, the number of individuals in placebo group, patients\' age, gender, BMI, diabetes duration, baseline HbA1c, duration of follow-up, and the changes of HbA1c and body weight in placebo group were all documented. If there is any disagreement, it would be resolved by discussion with another author (Yang WJ).

Definition of Asian and Caucasian {#sec2-4}
---------------------------------

All the data would be divided according to the ethnicity of the population included. If the trial involved more than 50% Caucasian population of all patients, it would be classified as in Caucasian group; if the trial was done mainly in Asian population (\>50%), it would be classified as in Asian group.\[[@ref17][@ref18][@ref19]\]

Statistical analysis {#sec2-5}
--------------------

To compare the baseline variables between Asian and Caucasian population, data were expressed as mean ± standard deviation and were compared using *t*-test. A two-sided *P* \< 0.05 was considered statistically significant. The primary end point of this meta-analysis was absolute HbA1c change relative to baseline in placebo treatment group in Asian and Caucasian T2DM patients. The mean difference (MD) in the placebo group was calculated as the change from baseline and 95% confidence interval (*CI*) was also shown. The measures of effect for all continuous variables were the differences from baseline to end point. When the standard deviations (SDs) for these differences were missing, we calculated the SD of the difference with the following formula:\[[@ref21]\]

SD~paired\ difference~^2^ = SD~pretreatment\ value~^2^ + SD~posttreatment\ value~^2^ − 2 × *r ×* SD~pretreatment\ value~ × SD~posttreatment\ value~. We used a conservative correlation coefficient (r) of 0.4.

SD~paired\ difference~= √SD~paired\ difference~^2^

Treatment effects were estimated by random-effect or fixed-effect pairwise meta-analysis. Higgins *I*^2^ statistics were used to quantify the percentage of the total variance in the summary estimate due to between-study heterogeneity. Publication bias was assessed via a funnel plot vision. Meta-regression analysis was also made for the association analysis between placebo effect in HbA1c changes and baseline characteristics. Statistical testing was two-sided, with *P* \< 0.05 considered statistically significant. All statistical analyses were performed with the STATA statistical software package (Version 11.0, StataCorp, College Station, TX, USA). We conducted this study according to the PRISMA guidelines.\[[@ref22]\]

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Outlines of the studies included {#sec2-6}
--------------------------------

[Figure 1](#F1){ref-type="fig"} indicates the study selection process. This study included 63 studies with a total of 7096 Asian patients involved and 262 studies with a total of 27,477 Caucasian patients recruited. In SU treatment group, there were 22 studies conducted in Caucasian population, but no study was found to recruit Asians. In MET treatment group, there was one study conducted in Asians and 16 studies conducted in Caucasians. There were eight studies in Asians and 35 studies in Caucasians with AGI treatment and 12 studies in Asians and 72 studies in Caucasians with TZD treatment. In DPP-4i treatment, there were 23 studies in Asians and 46 studies in Caucasians. In SGLT2i treatment, there were 11 studies in Asians and 38 studies in Caucasians. Moreover, there were eight studies in Asian population and 33 studies in Caucasian population with GLP-1RA treatment compared with placebo \[Supplementary Tables [S1](#T1){ref-type="table"} and [S2](#T2){ref-type="table"}\].

![The flowchart of included studies. AGI: Alpha glucosidase inhibitor; SU: Sulfonylurea; MET: Metformin; TZD: Thiazolidinedione; DPP4i: Dipeptidyl peptidase-4 inhibitors; SGLT2i: Sodium-glucose cotransporter 2 inhibitors; GLP-1RA: Glucagon-like peptide-1 receptor agonist.](CMJ-131-1605-g001){#F1}

###### 

Studies in Asian population

  Author, year                                         Study duration   Treatment group               Number of patients   Age (years)    Men (%)   BMI (kg/m^2^)   DM duration (years)   Baseline HbA1c (%)
  ---------------------------------------------------- ---------------- ----------------------------- -------------------- -------------- --------- --------------- --------------------- --------------------
  **MET versus placebo, monotherapy**                                                                                                                                                     
                                                                                                                                                                                          
  Fujioka, 2005                                        24 weeks         Placebo                       79                   58 ± 11        63        28.9 ± 3.5      3.2 ± 2.6             7.9 ± 0.9
  Fujioka, 2005                                        16 weeks         Placebo                       117                  54 ± 10        49        30.7 ± 4.1      2.7 ± 2.7             8.3 ± 1.1
                                                                                                                                                                                          
  **AGI versus placebo, monotherapy**                                                                                                                                                     
                                                                                                                                                                                          
  Chan, 1998                                           24 weeks         Placebo                       63                   54 (10)        50.8      /               2.1 ± 3.4             /
  Hotta, 1993                                          24 weeks         Placebo                       20                   47.9           22.2      /               4.4                   10.3
                                                                                                                                                                                          
  **AGI versus placebo, add-on therapy**                                                                                                                                                  
                                                                                                                                                                                          
  Hsieh, 2011                                          24 weeks         Placebo + SU                  53                   59 ± 10.7      51.4      /               /                     8.11 ± 0.77
  Hwu Chii-Min, 2003                                   18 weeks         Placebo + ins                 53                   54.7 ± 8.6     /         /               10.9 ± 6.1            
  Lin BJ, 2003                                         24 weeks         Placebo + SU                  32                   55.4 ± 8.5     37.5      /               5                     8.99 ± 0.95
  Lam KSL, 1998                                        24 weeks         Placebo                       44                   56.9 ± 1.3     43.2      24.1 ± 0.4      10.1 ± 0.8            9.4 ± 0.1
  Nemoto, 2011                                         12 weeks         Placebo + ins                 100                  /              /         /               /                     /
                                                                                                                                                                                          
  **TZD versus placebo, monotherapy**                                                                                                                                                     
                                                                                                                                                                                          
  Iwamoto, 1996                                        12 weeks         Placebo                       126                  57.4 ± 9.3     53.2      24.7 ± 3.4      7.5 ± 5.4             8.51 ± 1.46
  Kong, 2011                                           12 weeks         Placebo                       32                   54.0 ± 8.5     59.4      25.53 ± 4.03    5.85 ± 3.89           7.35 ± 0.62
  Nakamura, 2001                                       6 months         Placebo                       14                   /              /         /               /                     /
                                                                                                                                                                                          
  **TZD versus placebo, add-on therapy**                                                                                                                                                  
                                                                                                                                                                                          
  Hwang, 2008                                          12 months        Placebo+ SU                   46                   53.4 ± 9.7     45.7      26.6 ± 2.5      /                     /
  Iwamoto, 1996                                        12 weeks         Placebo + SU                  126                  58.7 ± 8.0     42.9      23.3 ± 3.1      /                     8.98 ± 1.45
  Kaku, 2009                                           28 weeks         Placebo + MET                 86                   53 ± 7.5       57        25.4 ± 3.6      5.6 ± 5.0             7.55 ± 0.9
  Kawamori, 1998                                       12 weeks         Placebo                       9                    60.6 ± 10.0    55.6      22.0 ± 3.0      11.9 ± 8.1            8.7 ± 1.3
  Mimura, 1994                                         3 months         Placebo                       6                    58 ± 2.1       50        21.3 ± 1.4      /                     9.7 ± 0.3
  Pan, 2002                                            12 weeks         Placebo + SU + MET            142                  /              /         /               /                     8.5 ± 1.12
  Sridhar, 2013                                        24 weeks         Placebo + glimepiride + MET   25                   44.0 ± 7.2     100       25.1 ± 3.2      2.9 ± 2.1             6.8 ± 0.4
  Yang, 2002                                           6 months         Placebo + SU                  34                   57.8 ± 8.9     38.2      25.84 ± 3.50    /                     9.7 ± 1.4
  Zhu, 2003                                            24 weeks         Placebo + SU                  105                  58.8 ± 7.7     46        25.1 ± 2.8      7.6                   9.8 ± 1.3
                                                                                                                                                                                          
  **DPP-4 inhibitor versus placebo, monotherapy**                                                                                                                                         
                                                                                                                                                                                          
  Iwamoto, 2010                                        12 weeks         Placebo                       73                   60.2 ± 8.0     68.5      24.1 ± 3.2      6.4 ± 5.5             7.74 ± 0.93
  JI 2016                                              24 weeks         Placebo                       127                  51.7 ± 10.2    61.7      26.0 ± 3.5      1.1 ± 0.2             8.7 ± 1.1
  Kawamori, 2012                                       12 weeks         Placebo                       80                   59.7 ± 8.9     71.3      24.3 ± 3.4      /                     7.95 ± 0.67
  Kikuchi, 2009                                        12 weeks         Placebo                       72                   60.4 ± 8.1     63.9      24.6 ± 3.1      7.1 ± 5.5             7.4 ± 0.8
  Mohan, 2009                                          18 weeks         Placebo                       178                  50.9 ± 9.3     60        24.9 ± 3.4      1.9 ± 1.6             8.8 ± 1.1
  Nonaka, 2008                                         12 weeks         Placebo                       76                   55.0 ± 8.0     66        25.1 ± 3.2      4.1 ± 4.6             7.7 ± 0.9
  Pan, 2012                                            24 weeks         Placebo                       284                  51.6 ± 10.3    54.6      25.9 ± 3.7      1.2 ± 2.6             8.2 ± 0.8
  Pan 2015                                             16 weeks         Placebo                       88                   53.2 ± 9.0     57.1      25.8 ± 3.0      2.0 ± 2.5             7.86 ± 0.79
  Seino, 2011                                          12 weeks         Placebo                       75                   59.1 ± 10.47   74.7      24.39 ± 3.69    6.83 ± 6.07           7.85 ± 0.89
  Wu 2015                                              24 weeks         Placebo                       23                   51.2 ± 7.5     50        24.11 ± 2.28                          8.00 ± 0.69
                                                                                                                                                                                          
  **DPP-4 inhibitor versus placebo, add-on therapy**                                                                                                                                      
                                                                                                                                                                                          
  Ji 2016                                              24 weeks         Placebo + MET                 484                  56.2 ± 10.8    49.6      25.1 ± 3.2      4.1 ± 4.3             7.2 ± 0.04
  Kadowaki, 2014                                       12 weeks         Placebo + glimepiride         98                   60.3 ± 7.8     67.3      24.6 ± 3.6      8.3 ± 6.2             8.4 ± 0.8
  Kaku, 2011                                           12 weeks         Placebo + PIO                 115                  60.1 ± 9.7     76/39     26.4 ± 4.4      6.7 ± 5.3             7.92 ± 0.85
  Kikuchi, 2010                                        12 weeks         Placebo + glimepiride         100                  60.3 ± 10.1    69        24.4 ± 2.6      9.8 ± 6.4             8 ± 0.8
  Lewin, 2012                                          18 weeks         Placebo + SU                  84                   56.2 ± 10.2    61.9      28.2 ± 5.1      /                     8.6 ± 0.7
  Ning 2016                                            24 weeks         Placebo + ins                 118                  58.5 ± 9.33    46.6      25.7 ± 2.68     11.4 ± 6.53           8.6 ± 0.93
  Owens, 2011                                          24 weeks         Placebo + MET + SU            263                  57.6 ± 9.7     48.3      28.2 ± 4.5      /                     8.14 ± 0.05
  Pan, 2012                                            24 weeks         Placebo + MET                 144                  54.5 ± 9.68    45.8      25.46 ± 3.09    5.15 ± 4.58           8.01 ± 0.82
  Pan 2015                                             16 weeks         Placebo + MET                 93                   53.4 ± 9.4     48.9      25.5 ± 3.9      5.5 ± 3.9             7.98 ± 0.75
  Pan 2015                                             16 weeks         Placebo + PIO                 63                   51.8 ± 10.4    62.9      26.1 ± 3.0      4.9 ± 4.7             7.96 ± 0.82
  Seino, 2011                                          12 weeks         Placebo + voglibose           75                   62.3 ± 10.5    48/27     24.42 ± 4.20    7.52 ± 6.03           8.12 ± 1.19
                                                                                                                                                                                          
  **DPP-4 inhibitor versus placebo, add-on therapy**                                                                                                                                      
                                                                                                                                                                                          
  Seino, 2012                                          24 weeks         Placebo + MET                 100                  52.1 ± 8.05    72        26.14 ± 4.58    6.04 ± 4.36           8.00 ± 0.86
  Wang 2015                                            24 weeks         Placebo + MET                 80                   56.5 ± 8.7     50        25.8 ± 4.0                            8.00 ± 0.80
  Yang 2015                                            24 weeks         Placebo + glimepiride         136                  58.7 ± 9.3     58.1      25.0 ± 2.8      6.9 ± 4.1             10.6 ± 2.3
  Yang, 2011                                           24 weeks         Placebo + MET                 287                  54.4 ± 10.1    48.7      26.1 ± 3.5      5.1 ± 4.0             7.9 ± 0.8
  Yang, 2012                                           24 weeks         Placebo + MET                 198                  55.1 ± 9.8     55        25.3 ± 3.6      7.3 ± 4.6             8.5 ± 0.9
  Zeng 2013                                            24 weeks         Placebo + MET + SU            48                   57.0 ± 8.9     52.1      25.6 ± 3.4                            8.10 ± 0.84
                                                                                                                                                                                          
  **SGLT2i versus placebo, monotherapy**                                                                                                                                                  
                                                                                                                                                                                          
  Ikeda, 2015                                          12 weeks         Placebo                       66                   53.9 ± 11.12   54.5      30.37 ± 5.466                         7.88 ± 0.694
  Inagaki, 2013                                        12 weeks         Placebo                       75                   57.7 ± 11.0    72.0      26.41 ± 4.34                          7.99 ± 0.77
  Inagaki, 2014                                        24 weeks         Placebo                       93                   58.2 ± 11.0    64.5      25.85 ± 4.39                          8.04 ± 0.70
  Ji, 2014                                             24 weeks         Placebo                       132                  49.9 ± 10.87   65.9      25.93 ± 3.64                          8.35 ± 0.95
  Kaku, 2013                                           12 weeks         Placebo                       54                   58.4 ± 10.0    79.6      /                                     8.12 ± 0.71
  Kaku, 2014                                           24 weeks         Placebo                       56                   56.8 ± 9.9     66.1      26.00 ± 4.11                          8.41 ± 0.78
  Kashiwagi, 2015                                      24 weeks         Placebo                       46                   65.7 ± 6.93    78.3      24.96 ± 3.362                         7.55 ± 0.526
  Kashiwagi, 2015                                      24 weeks         Placebo                       56                   57.7 ± 9.24    58.9      25.47 ± 3.092                         8.38 ± 0.738
  Roden, 2013                                          24 weeks         Placebo                       228                  54.9 ± 10.9    54        28.7 ± 6.2                            7.91 ± 0.78
                                                                                                                                                                                          
  **SGLT2i versus placebo, add-on therapy**                                                                                                                                               
                                                                                                                                                                                          
  Ji, 2015                                             18 weeks         Placebo                       226                  55.8 ± 9.4     55.6      25.5 ± 3.6                            7.9 ± 0.9
  Roden, 2015                                          76 weeks         Placebo                       228                  54.9 ± 10.9    53.9      28.7 ± 6.2                            7.91 ± 0.78
                                                                                                                                                                                          
  **GLP-1RA versus placebo, monotherapy**                                                                                                                                                 
                                                                                                                                                                                          
  Miyagawa, 2015                                       26 weeks         Placebo                       70                   57.7 ± 8.3     79        25.2 ± 3.2                            8.20 ± 0.83
  Seino, 2008                                          14 weeks         Placebo                       46                   57.5 ± 8.7     63        23.77 ± 2.63                          8.43 ± 1.02
                                                                                                                                                                                          
  **GLP-1RA versus placebo, add-on therapy**                                                                                                                                              
                                                                                                                                                                                          
  Gao, 2009                                            12 weeks         Placebo + MET/SU              232                  54 ± 9         41        26.1 ± 3.4                            8.3 ± 1.0
  Kadowaki, 2009                                       12 weeks         Placebo + SU                  40                   60.5 ± 10.2    75        25.8 ± 4.6                            8.1 ± 0.7
  Kaku, 2010                                           24 weeks         Placebo + SU                  88                   58.6 ± 9.7     65        24.9 ± 4.0                            8.45 ± 0.99
  Kim, 2007                                            15 weeks         Placebo                       15                   55 ± 9         36        36 ± 6                                8.6 ± 1.4
  Pan CY, 2014                                         24 weeks         Placebo + MET ± SU            194                  55.1 ± 10.5    46.9      27.1 ± 3.8                            7.85 ± 0.71
  Seino Y, 2012                                        24 weeks         Placebo + basal ins ± SU      157                  58.0 ± 10.1    51        25.2 ± 3.9                            8.52 ± 0.78

Data are given as the mean ± SD. BMI: Body mass index; DM: Diabetes mellitus; HbA1c: Glycosylated hemoglobin; MET: Metformin; AGI: Alpha glucosidase inhibitors; TZD: Thiazolidinediones; DPP-4: Dipeptidyl peptidase-4 inhibitors; SGLT2i: Sodium-glucose cotransporter 2 inhibitors; GLP-1RA: Glucagon-like peptide-1 analogs; SD: Standard deviation; PIO: Pioglitazone; /: No reported data; ins: Insulin.

###### 

Studies in Caucasian population

  Author, year                                         Study duration   Treatment group                                     Number of patients   Age (years)     Men (%)     BMI (kg/m^2^)        DM duration (years)   Baseline HbA1c (%)
  ---------------------------------------------------- ---------------- --------------------------------------------------- -------------------- --------------- ----------- -------------------- --------------------- --------------------
  **SU versus placebo, monotherapy**                                                                                                                                                                                    
                                                                                                                                                                                                                        
  Coniff, 1995                                         36 weeks         Placebo                                             62                   56.3            52          29.9                 5.5                   7.1
  Ebeling, 2001                                        6 months         Placebo                                             10                   /               /           31.9 ± 1.5           /                     8.6 ± 0.2
  Fischer, 2003                                        16 weeks         Placebo                                             25                   58.6 ± 6.3      68          /                    6.4 ± 0.9             8.3 ± 0.2
  Goldberg, 1996                                       14 weeks         Placebo                                             74                   60.4            64.9        /                    6                     7.8
  Hanefeld, 2002                                       16 weeks         Placebo                                             8                    59 ± 1.6        75          27.2 ± 1.1           6.8 ± 1.6             8.7 ± 0.6
  Hoffmann, 1994                                       24 weeks         Placebo                                             30                   56.9 ± 6.7      40          26.8 ± 1.5           1.0 ± 0.9             8.29 ± 0.37
  Madsbad, 2004                                        12 weeks         Placebo                                             29                   57 ± 9.4        69          30.3 ± 4.2           3.8 ± 3.4             7.8 ± 0.9
  Rosenstock, 1996                                     14 weeks         Placebo                                             79                   61.1 ± 9.7      67          /                    6                     8.0 ± 1.1
  Scott, 2007                                          12 weeks         Placebo                                             125                  55.3 ± 9.7      62.4        31.6 ± 5.8           4.7 ± 4.2             7.9 ± 1.0
  Segal, 1997                                          24 weeks         Placebo                                             42                   59              57.1        29.1                 /                     8.25
  Simonson, 1997                                       16 weeks         Placebo                                             69                   60.2            76.8        29.7                 7.5                   8.3 ± 0.2
                                                                                                                                                                                                                        
  **SU versus placebo, add-on therapy**                                                                                                                                                                                 
                                                                                                                                                                                                                        
  Burant, 2012                                         12 weeks         Placebo                                             61                   52.9 ± 11.3     43          31.2 ± 5.0           5.6 ± 4.8             8.46 ± 1.07
  Camerini-Davalos, 1994                               3 years          Placebo + ins                                       29                   46.4 ± 2.0      /           24.3 ± 0.4           14.1                  10.3 ± 0.3
  Feinglos, 2005                                       16 weeks         Placebo + MET                                       61                   58.8 ± 10.0     41          32.1 ± 4.9           4.6                   7.64
  Forst, 2010                                          12 weeks         Placebo + MET                                       71                   60.1 ± 8.1      62          32.2 ± 4.2           6.2 ± 5.1             8.4 ± 0.7
  Karlander, 1991                                      325 days         Placebo + ins                                       /                    /               /           /                    /                     10.3
  LeWitt, 1989                                         6 months         Placebo + ins                                       /                    /               /           /                    /                     /
  Lins, 1988                                           12 weeks         Placebo + ins                                       10                   60 ± 3          60          /                    /                     10.7 ± 0.5
  Nauck, 2009                                          26 weeks         Placebo + MET                                       121                  56 ± 9          60          31.6 ± 4.4           8 ± 6                 8.4 ± 1.1
  Riddle, 1992                                         16 weeks         Placebo + ins                                       10                   /               /           /                    /                     /
  Riddle, 1989                                         4 months         Placebo + ins                                       10                   /               /           /                    /                     /
  Riddle, 1998                                         24 weeks         Placebo + ins                                       73                   58 ± 8          54.8        33.7 ± 5.4           7 ± 4                 9.9
  Roberts, 2005                                        26 weeks         Placebo + MET + SU                                  77                   56.4 ± 10.0     62.3        32.76 ± 5.11         7.9 ± 4.9             8.15 ± 0.65
  Schade, 1987                                         4 months         Placebo + ins                                       8                    /               /           /                    /                     /
  Stenman, 1988                                        4 months         Placebo + ins                                       8                    /               /           /                    /                     /
  Stuart, 1997                                         12 weeks         Placebo + ins                                       9                    /               /           /                    /                     7.4 ± 0.3
  Clark JCM, 1997                                      /                Placebo                                             /                    /               /           /                    /                     /
                                                                                                                                                                                                                        
  **MET versus placebo, monotherapy**                                                                                                                                                                                   
                                                                                                                                                                                                                        
  Chiasson, 2001                                       36 weeks         Placebo                                             83                   57.7 ± 9.9      67.5        31.1 ± 4.4           5.1 ± 4.9             8.1 ± 0.7
  DeFronzo, 1995                                       29 weeks         Placebo                                             146                  53 ± 1          42.5        29.2 ± 0.3           6.0 ± 0.6             8.2 ± 0.2
  Dornan, 1991                                         8 months         Placebo                                             30                   55 ± 1          /           30 ± 1               /                     11.8 ± 0.4
  Fonseca, 2013                                        12 weeks         PBO                                                 69                   53.4 ± 9.7      46.4        30.9 ± 5.5           4.64 ± 5.93           7.84 ± 0.78
  Garber, 1997                                         14 weeks         Placebo                                             79                   55 ± 11         56          /                    /                     9.9 ± 1.9
  Grant, 1996                                          6 months         Placebo                                             23                   /               /           /                    /                     /
  Goldstein, 2007                                      24 weeks         Placebo                                             165                  /               /           /                    /                     8.68 ± 1.00
  Hällsten, 2002                                       26 weeks         Placebo                                             14                   57.7 ± 1.9      71.4        30.3 ± 1.2           /                     6.3 ± 0.1
  Haak, 2012                                           24 weeks         Placebo                                             72                   55.7 ± 11.0     50          28.6 ± 5.2           /                     8.7 ± 1.0
  Horton, 2000                                         24 weeks         Placebo                                             172                  59.6 ± 10.9     60.5        29.2 ± 3.9           4.6 ± 4.7             8.3 ± 1.1
  Johnson, 1993                                        12 weeks         Placebo                                             4                    /               /           /                    /                     /
  List, 2009                                           12 weeks         PBO                                                 54                   53 ± 11         56          32 ± 5               /                     7.9 ± 0.9
  Nagi, 1993                                           12 weeks         Placebo                                             /                    /               /           /                    /                     /
  Natali, 2004                                         16 weeks         PBO                                                 22                   58 ± 9          81.8        30.2 ± 3.1           3.4 ± 3.4             7.6 ± 0.8
  Tessari, 1994                                        4 weeks          Placebo                                             6                    60 ± 3          33.3        28 ± 1               /                     6.7 ± 0.3
  Viljanen, 2005                                       26 weeks         Placebo                                             11                   58.7 ± 8.3      81.8        29.8 ± 4.1           /                     6.2 ± 0.7
                                                                                                                                                                                                                        
  **MET versus placebo, add-on therapy**                                                                                                                                                                                
                                                                                                                                                                                                                        
  Avileés-Santa, 1999                                  24 weeks         Placebo + ins                                       22                   54.6 ± 7.8      45.5        /                    10.1 ± 4.7            9.1 ± 1.5
  Douek, 2005                                          12 months        Placebo + ins                                       91                   58 ± 7.7        62.6        31.5 ± 4.3           10 ± 5.2              10.0 ± 1.5
  Gram, 2011                                           2 years          Placebo + ins                                       46                   55.8 ± 7.7      71.7        34.0 ± 6.0           7.3 ± 4.3             8.7 ± 1.3
                                                                        Placebo + ASP                                       48                   57.1 ± 8.5      47.9        33.7 ± 5.0           9.1 ± 5.5             8.5 ± 1.2
  Hermann, 2001                                        12 months        Placebo + ins                                       19                   58.1 ± 9.7      63.2        32.6 ± 3.8           13                    8.7 ± 1.0
  Kooy, 2009                                           4.3 years        Placebo + ins                                       194                  59 ± 11         50          30 ± 5               12 ± 8                7.9 ± 1.2
  Willms, 1999                                         12 weeks         Placebo + SU                                        29                   59.2 ± 9.4      58.6        /                    10.0 ± 6.4            10.6 ± 1.6
                                                                                                                                                                                                                        
  **AGI versus placebo, monotherapy**                                                                                                                                                                                   
                                                                                                                                                                                                                        
  Calle-Pascuac, 1996                                  16 weeks         Placebo                                             20                   /               /           35.9 ± 7.6           /                     6.4 ± 1.3
  Chiasson, 1994                                       1 year           Placebo                                             39                   /               /           28.8 ± 0.5           /                     /
  Chiasson, 2001                                       36 weeks         Placebo                                             83                   57.7 ± 9.9      67.5        31.1 ± 4.5           5.1 ± 4.9             8.1 ± 0.7
  Coniff, 1994                                         36 weeks         Placebo                                             98                   55.6 ± 1.0      45          31.5                 3                     6.65
  Coniff, 1995                                         16 weeks         Placebo                                             64                   54              58          32                   5                     8.67
  Coniff, 1995                                         36 weeks         Placebo                                             62                   56.3            52          29.9                 5.5                   7.1
  Delgado, 2002                                        4 months         Placebo                                             8                    /               /           34.4 ± 2.8           /                     7.5 ± 0.6
  Derosa, 2011                                         7 months         Placebo                                             92                   /               48.9        26.8 ± 0.9           /                     6.7 ± 0.5
                                                                                                                                                                                                                        
  **AGI versus placebo, monotherapy**                                                                                                                                                                                   
                                                                                                                                                                                                                        
  Fischer, 2003                                        16 weeks         Placebo                                             25                   58.6 ± 6.3      /           27.0 ± 0.7           6.4 ± 0.9             8.3 ± 0.2
  Gentile, 2001                                        28 weeks         Placebo                                             48                   /               /           /                    /                     8.7 ± 0.9
  Hanefeld, 2002                                       16 weeks         Placebo                                             8                    59 ± 1.6        75          27.2 ± 1.1           6.8 ± 1.6             8.7 ± 0.6
  Hanefeld, 2009                                       20 weeks         Placebo                                             45                   59.92 ± 10.0    /           30.78 ± 3.70         /                     6.09 ± 0.66
  Hasche, 1999                                         24 months        Placebo                                             48                   /               /           26.2 ± 2.4           /                     8.7 ± 0.9
  Hoffmann, 1997                                       24 weeks         Placebo                                             32                   60.2 ± 8.6      38          26.3 ± 2.2           3.6 ± 2.8             9.4 ± 0.9
  Hoffmann, 1994                                       24 weeks         Placebo                                             30                   56.9 ± 6.7      40          26.8 ± 1.5           12.1 ± 10.8           8.29 ± 0.37
  Johnston, 1998                                       1 year           Placebo                                             105                  56.9 ± 1.3      51          32.0 ± 0.9           4.5 ± 0.7             8.62 ± 0.18
  Johnston, 1998-2                                     1 year           Placebo                                             120                  53.9            /           30.6                 4.8                   8.53
  Josse, 2003                                          12 months        Placebo                                             99                   70.3 ± 0.5      /           28.6 ± 0.4           4.8 ± 0.5             7.3 ± 0.1
  Kirkman, 2006                                        5 years          Placebo                                             110                  53.7 ± 11.7     34.6        35.2 ± 7.1           /                     6.33 ± 0.63
  Meneilly, 2000                                       12 months        Placebo                                             23                   70 ± 1          /           28.0 ± 1.0           /                     7 ± 0.2
  Rosenbaum, 2002                                      22 weeks         Placebo                                             20                   62 ± 9.7        40          31.7 ± 3.9           6.8                   6.3 ± 2.1
  Segal, 1997                                          24 weeks         Placebo                                             42                   59              57.1        29.1                 /                     8.25
  Scott, 1999                                          16 weeks         Placebo                                             52                   57 ± 8          65          29.0 ± 3.0           2.17 ± 1.42           6.89 ± 0.85
  Wagner, 2006                                         12 weeks         Placebo                                             17                   54 (50--58)     82.3        28.7 (25.6--30.30)   4 (2--5)              6.6 (6.1-7.1)
                                                                                                                                                                                                                        
  **AGI versus placebo, add-on therapy**                                                                                                                                                                                
                                                                                                                                                                                                                        
  Bachmann, 2003                                       78 weeks         Placebo + SU                                        166                  63.3 ± 7.2      43.3        29.0 ± 2.9           8 ± 12.5              9.38 ± 0.73
  Chiasson, 1994                                       1 year           Placebo + MET                                       /                    /               /           29.4 ± 0.6           /                     /
                                                                        Placebo + SU                                        /                    /               /           27.8 ± 0.4           /                     /
                                                                        Placebo + ins                                       /                    /               /           30.2 ± 0.5           /                     /
  Chiasson, 2001                                       36 weeks         Placebo + MET                                       83                   57.9 ± 8.6      73.5        30.7 ± 5.1           7.5 ± 7.4             8.2 ± 0.9
  Halimi, 2000                                         6 months         Placebo + MET                                       70                   55 ± 10         62.8        29.7 ± 3.3           9 ± 7.5               8.5 ± 1.1
  Kelley, 1998                                         24 weeks         Placebo + ins                                       73                   60.8            48          31.1                 12.3                  8.69
  Mitrakou, 1998                                       24 weeks         Placebo + ins                                       60                   57.4 ± 5.8      61.7        24.5 ± 3.4           7.9 ± 3.2             9.9 ± 0.4
  Phillips, 2003                                       24 weeks         Placebo + MET                                       43                   62.39 ± 8.02    76.7        30.09 ± 2.85         6.06 ± 5.32           7.82 ± 0.83
  Schnell, 2007                                        20 weeks         Placebo + ins                                       81                   62.3 ± 7.4      /           29.9 ± 4.5           9.6 ± 5.1             9.4 ± 1
  Standl, 1999                                         24 weeks         Placebo + ins                                       24                   62.9 ± 9.4      /           24.1 ± 2.0           12.2 ± 5.7            11.0 ± 1.2
  Standl, 2001                                         24 weeks         Placebo + SU + MET                                  68                   61 ± 8          54.4        27.9 ± 3.5           9                     8.84 ± 0.66
  Willms, 1999                                         12 weeks         Placebo + SU                                        29                   59.2 ± 9.4      58.6        /                    10.0 ± 6.4            10.6 ± 1.6
  Van Gaal, 2001                                       32 weeks         Placebo + MET                                       75                   57.9 ± 8.5      49.3        29.7 ± 3.9           6                     8.4 ± 1
                                                                                                                                                                                                                        
  **TZD versus placebo, monotherapy**                                                                                                                                                                                   
                                                                                                                                                                                                                        
  Aronoff, 2000                                        26 weeks         Placebo                                             79                   /               /           /                    /                     10.4 ± 0.22
  Caballero, 2003                                      12 weeks         Placebo                                             /                    /               /           /                    /                     /
  Caballero, 2003                                      /                Placebo                                             /                    /               /           /                    /                     /
  Caballero, 2003                                      /                Placebo                                             /                    /               /           /                    /                     /
  Carey, 2002)                                         16 weeks         Placebo                                             17                   57.9 ± 10.7     76.5        31.3 ± 3.6           3.1 ± 3.3             7.1 ± 1.4
  Chou, 2012                                           26 weeks         Placebo                                             137                  55.4 ± 12.32    48.9        30.1 ± 5.43          4.9 ± 6.13            7.7 ± 0.54
  Ebeling, 1999                                        16 weeks         Placebo                                             12                   63.5 ± 2.8      50          33.1 ± 1.0           14.3 ± 1.9            8.8 ± 0.3
  Ebeling, 2001                                        6 months         Placebo                                             10                   /               /           31.9 ± 1.5           /                     8.6 ± 0.2
  Fonseca, 1998                                        6 months         Placebo                                             79                   /               /           /                    /                     /
  Fonseca, 1998                                        26 weeks         Placebo                                             8                    52.6 ± 7.5      37.5        39.6 ± 13.4          /                     10.1 ± 1.43
  Gastaldelli, 2006                                    12 weeks         Placebo                                             13                   56 ± 2          61.5        30.2 ± 1.0           3 ± 1                 8.2 ± 0.4
  Gastaldelli, 2007-1                                  4 months         Placebo                                             12                   56 ± 2          66.7        29.8 ± 1.2           2 ± 1                 8.1 ± 0.4
  Haffner, 2002                                        26 weeks         Placebo                                             95                   59.8 ± 10.5     61.1        30.1 ± 3.9           4.5 ± 4.8             8.7 ± 1.5
  Hällsten, 2002                                       26 weeks         Placebo                                             14                   57.7 ± 1.9      71.4        30.3 ± 1.2           /                     6.3 ± 0.1
  Herz, 2003                                           16 weeks         Placebo                                             99                   58.0 ± 10.7     49.5        31.7 ± 4.5           1.5 ± 2.5             /
  Juhl, 2003                                           13 weeks         Placebo                                             10                   54 ± 9          60          31.7 ± 1.9           /                     6.8 ± 1.0
  Khan, 2006                                           26 weeks         Placebo                                             21                   54.8 ± 8.65     28.6        32.0 ± 4.23          /                     8.62 ± 0.323
  Kumar, 1996                                          12 weeks         Placebo                                             49                   57              73.5        28.9 ± 4.6           7                     7.2
  Lautamäki, 2005                                      16 weeks         Placebo                                             27                   63.2 ± 7.4      70.4        29.6 ± 3.4           6.8 ± 5.9             7.1 ± 0.9
                                                                                                                                                                                                                        
  **TZD versus placebo, monotherapy**                                                                                                                                                                                   
                                                                                                                                                                                                                        
  Miyazaki, 2001                                       12 weeks         Placebo                                             14                   /               /           30.1 ± 1.0           /                     8.3 ± 0.4
  Miyazaki, 2001                                       16 weeks         Placebo                                             11                   /               /           29.5 ± 1.3           /                     7.9 ± 0.3
  Miyazaki, 2002                                       26 weeks         Placebo                                             11                   58 ± 3          27.3        32.8 ± 1.6           /                     8.6 ± 0.5
  Miyazaki, 2007                                       3 months         Placebo                                             14                   56 ± 2          64.3        30 ± 1               /                     8.3 ± 0.4
  Natali, 2004                                         16 weeks         Placebo                                             22                   58 ± 9          81.8        30.2 ± 3.1           3.4 ± 3.4             7.6 ± 0.8
  Ozgul, 2008                                          12 weeks         Placebo                                             10                   /               /           29.2 ± 2.3           /                     6.39 ± 1.1
  Ozgul, 2010                                          12 weeks         Placebo                                             21                   /               /           29.6 ± 4.1           /                     7.3 ± 0.9
  Patel, 1999                                          12 weeks         Placebo                                             75                   56.8 ± 11.50    69.3        28.9 ± 3.98          4.2                   9.1
  Phillips, 2001                                       16 weeks         Placebo                                             173                  57.7 ± 9.2      68.8        29.1 ± 4.2           6.6 ± 6.9             8.9 ± 1.5
  Raskin, 2000                                         8 weeks          Placebo                                             69                   60.06 ± 9.39    59.4        30.44 ± 4.15         5.6 ± 5.19            8.7 ± 1.63
  Rosenblatt, 2001                                     16 weeks         Placebo                                             96                   55.2 ± 10.0     56.2        30.7 ± 5.0           /                     10.42 ± 1.70
  Rosenstock, 2002                                     16 weeks         Placebo                                             148                  58              59          20-38                0.2-37.9              8.2 ± 1.2
  Scherbaum, 2002                                      26 weeks         Placebo                                             84                   59.1            56          29.2                 5.6                   8.75
  Sourij, 2006                                         12 weeks         Placebo                                             21                   /               /           /                    /                     6.1 ± 0.5
  Tan, 2005                                            24 weeks         Placebo                                             6                    /               /           30.8 ± 1.04          /                     7.52 ± 0.38
  Truitt, 2010                                         26 weeks         Placebo                                             92                   55.3 ± 9.3      51.1        32.2 ± 5.8           6.7 ± 5.6             8.21 ± 0.98
  Viljanen, 2005                                       26 weeks         Placebo                                             11                   58.7 ± 8.3      81.8        29.8 ± 4.1           6.2 ± 0.7             6.2 ± 0.7
  Wallace, 2004                                        12 weeks         Placebo                                             11                   62.6 ± 10.0     72.7        28.9 ± 2.8           2.5                   6.7 ± 0.9
                                                                                                                                                                                                                        
  **TZD versus placebo, add-on therapy**                                                                                                                                                                                
                                                                                                                                                                                                                        
  Barnett, 2003                                        26 weeks         Placebo + SU                                        87                   54.1            75          26.4                 6.5                   9.06 ± 1.03
  Berhanu, 2007                                        20 weeks         Placebo + ins ± MET                                 112                  52.5 ± 11.07    41.1        31.8 ± 6.2           8.5 ± 5.43            8.6 ± 0.13
  Bertrand, 2010                                       12 months        Placebo                                             95                   65.9 ± 6.9      92          29.5 ± 4.6           8.4 ± 6.9             6.9 ± 0.8
  Brackenridge, 2009                                   3 months         Placebo ± MET                                       8                    60.8 ± 3.45     87.5        32.0 ± 1.56          2.9 ± 0.4             6.6 ± 0.14
  Buras, 2005                                          12 weeks         Placebo                                             39                   57 ± 9          66.7        32.6 ± 5.0           8 ± 9                 7.9 ± 1.4
  Buse, 1998                                           26 weeks         Placebo + ins                                       71                   57 ± 11         49          34.5 ± 7.2           /                     9.0 ± 1.4
  Buysschaert, 1999                                    16 weeks         Placebo + SU                                        85                   60              51.8        /                    7.77                  8.5
  Charpentier, 2009                                    7 months         Placebo                                             147                  59.2 ± 9.6      66.2        29.2 ± 3.1           12.1 ± 7.9            8.2 ± 0.6
  Colca, 2013                                          12 weeks         Placebo                                             56                   53              48          /                    /                     7.98
  Dailey, 2004                                         24 weeks         Placebo + glyburide/MET                             184                  57 ± 10         61          32 ± 5               9 ± 6                 8.1 ± 0.8
  Davidson, 2007                                       24 weeks         Placebo + RSG                                       116                  53 ± 10.4       48.3        31.9 ± 5.6           6.2 ± 5.3             9.4 ± 1.4
  Derosa, 2008                                         6 months         Placebo + MET                                       61                   54 ± 3          47.5        28.4 ± 1.7           4 ± 1                 8.0 ± 0.9
  Einhorn, 2000                                        16 weeks         Placebo + MET                                       160                  55.7 ± 9.92     60          32.12 ± 5.5          9.75 ± 1.3            /
  Fonseca, 2000                                        26 weeks         MET + placebo                                       113                  58.8 ± 9.2      74.3        30.3 ± 4.4           7.3 ± 5.7             8.6 ± 1.3
  Galle, 2012                                          6 months         Placebo + ins                                       19                   69.6 ± 9.4      68.4        30.3 ± 4.6           12.4 ± 8.2            7.7 ± 0.9
  Gastaldelli, 2007-2                                  4 months         Placebo + SU                                        10                   55 ± 4          40          29.9 ± 1.4           5 ± 2                 8.3 ± 0.4
  Gastaldelli, 2009                                    16 weeks         Placebo                                             10                   62 ± 2          /           29.7 ± 0.8           /                     /
  Gòmez-Pérez, 2002                                    26 weeks         MET + placebo                                       34                   53.4 ± 7.5      29.4        28.5 ± 3.9           9.1 ± 5.6             /
  Gram, 2011                                           2 years          Placebo + ins                                       46                   55.8 ± 7.7      71.7        34.0 ± 6.0           7.3 ± 4.3             8.7 ± 1.3
                                                                        Placebo + ASP                                       48                   57.1 ± 8.5      47.9        33.7 ± 5.0           9.1 ± 5.5             8.5 ± 1.2
  Grey, 2012                                           6 months         Placebo                                             10                   57.9 ± 15.2     50          33.2 ± 4.1           /                     7.1 ± 1.0
  Henriksen, 2011                                      26 weeks         Placebo + ins                                       106                  60.9 ± 7.8      62          33.9 ± 5.5           12.6 ± 7.3            8.5 ± 1.3
  Hollander, 2007                                      24 weeks         Placebo + ins                                       186                  53.8 ± 10.2     46.2        33.0 ± 6.5           12.6 ± 8.6            9.1 ± 1.3
  Kelly, 1999                                          12 weeks         Placebo                                             10                   58.6 ± 7.5      80          28.6 ± 3.76          /                     8.38 ± 1.52
  Kipnis, 2001                                         16 weeks         Placebo + SU                                        187                  56.9 ± 8.9      58          32.0 ± 4.9           /                     9.9 ± 0.2
  Lebovitz, 2001                                       /                Placebo                                             1842                 /               /           /                    /                     /
  Marre, 2009                                          26 weeks         Placebo + SU                                        114                  54.7 ± 10.0     47          30.3 ± 5.4           6.5                   8.4 ± 1.0
  Mattoo, 2005                                         6 months         Placebo + ins                                       147                  58.9 ± 6.9      42.9        31.8 ± 5.0           13.4 ± 6.1            8.79 ± 0.10
  Negro, 2005                                          12 months        Placebo + MET                                       19                   59 ± 8          63.2        28.7 ± 1.9           6.6 ± 2.9             8.1 ± 0.5
                                                                                                                                                                                                                        
  **TZD versus placebo, add-on therapy**                                                                                                                                                                                
                                                                                                                                                                                                                        
  Osende, 2001                                         3 months         Placebo                                             21                   57.0 ± 1.7      52.4        31.5 ± 2.1           /                     9.2 ± 0.2
  Raskin, 2001                                         26 weeks         Placebo + ins                                       104                  55.6 ± 10.3     55.8        32.7 ± 6.2           11.7 ± 6.2            8.9 ± 1.1
  Reynolds, 2002                                       6 months         Placebo + ins                                       /                    /               /           36.3 ± 1.8           /                     9.8 ± 0.5
  Rosenstock, 2008                                     26 weeks         Placebo + glimepiride 3 mg/d                        57                   65 ± 9          60          29.1 ± 4.5           6.6 ± 3.9             7.9 ± 1.3
  Scheen, 2009                                         34.5 months      Placebo +MET                                        261                  60.3 ± 7.9      67          32.0 ± 5.3           5.6 ± 5.4             7.6 ± 1.2
                                                                        Placebo + SU                                        493                  62.9 ± 7.8      71          29.9 ± 4.3           6.9 ± 6.1             7.7 ± 1.4
  Schwartz, 1998                                       26 weeks         Placebo + ins                                       118                  56 ± 10         51          35.0 ± 6.3           10 ± 4                9.4 ± 1.1
  Smith, 2005                                          24 weeks         Placebo                                             21                   53.1 ± 9.3      47.6        31.9 ± 5.0           /                     6.46 ± 0.72
  Wolffenbuttel, 2000                                  26 weeks         Placebo + SU                                        192                  61.9 ± 9.1      57.3        28.1 ± 4.1           8                     9.21 ± 1.30
  Yale, 2001                                           24 weeks         Placebo + MET + SU                                  99                   60 ± 0.9        58          30.0 ± 0.4           10.8 ± 0.6            9.7 ± 0.1
                                                                                                                                                                                                                        
  **DPP-4 inhibitor versus placebo, monotherapy**                                                                                                                                                                       
                                                                                                                                                                                                                        
  Aschner, 2006                                        24 weeks         Placebo                                             244                  /               /           /                    /                     8.03 ± 0.82
  DeFronzo, 2008                                       26 weeks         Placebo                                             64                   /               /           /                    /                     /
  de Jager, 2007                                       24 weeks         Placebo                                             94                   52.2 ± 11.2     47.9        32.6 ± 5.6           1.6 ± 2.5             8.4 ± 0.8
  Goldstein, 2007                                      24 weeks         Placebo                                             165                  /               /           /                    /                     8.68 ± 1.00
  Haak, 2012                                           24 weeks         Placebo                                             72                   55.7 ± 11.0     50          28.6 ± 5.2           /                     8.7 ± 1.0
  Pi-Sunyer, 2007                                      24 weeks         Placebo                                             92                   52.0 ± 12.0     54.3        32.7 ± 6.4           2.5 ± 3.7             8.5 ± 0.8
  Prato, 2011                                          24 weeks         Placebo                                             167                  54.4 ± 10.3     47.3        29.08 ± 4.84         /                     8.0 ± 0.07
  Raz I, 2006                                          18 weeks         Placebo                                             103                  /               /           /                    /                     8.05 ± 0.9
  Ristic, 2005                                         12 weeks         Placebo                                             55                   54.6 ± 10.6     56.9        31.6 ± 4.41          2.28 ± 2.99           7.76 ± 0.83
  Rosenstock, 2009                                     24 weeks         Placebo                                             95                   53.91 ± 12.32   49.5        30.93 ± 4.26         2.3 ± 2.7             7.9 ± 0.9
  Rosenstock, 2008                                     12 weeks         Placebo                                             67                   55.2 ± 9.8      63          31.1 ± 4.46          1.8                   8.0 ± 0.88
  Scherbaum, 2008                                      52 weeks         Placebo                                             150                  62.8 ± 11.0     59.3        30.0 ± 4.9           2.7 ± 3.2             6.8 ± 0.4
  Scott, 2007                                          12 weeks         Placebo                                             125                  55.3 ± 9.7      62.4        31.6 ± 5.8           4.7 ± 4.2             7.9 ± 1.0
  Strain, 2013                                         24 weeks         Placebo                                             139                  74.4 ± 4        38.1        30.5 ± 4.8           10.6 ± 6.9            7.9 ± 0.7
                                                                                                                                                                                                                        
  **DPP-4 inhibitor versus placebo, add-on therapy**                                                                                                                                                                    
                                                                                                                                                                                                                        
  Ahrén, 2004                                          12 weeks         Placebo + MET                                       51                   55.7 ± 11.0     66.7        30.2 ± 3.6           5.5 ± 3.7             7.8 ± 0.7
  Barnett, 2012                                        24 weeks         Placebo + ins                                       151                  57.3 ± 9.27     45          31.8 ± 4.76          12.2 ± 7.37           8.6 ± 0.86
  Bosi, 2007                                           24 weeks         Placebo + MET                                       130                  54.5 ± 10.3     53.1        33.2 ± 6.1           6.2 ± 5.3             8.3 ± 0.9
  Charbonnel, 2006                                     24 weeks         Placebo + MET                                       226                  /               /           /                    /                     8.03 ± 0.82
  DeFronzo, 2009                                       24 weeks         Placebo + MET                                       179                  /               /           /                    /                     /
  DeFronzo, 2012                                       26 weeks         Placebo + MET                                       129                  55.2 ± 9.9      47.3        30.6 ± 4.8           6.0 ± 5.0             8.5 ± 0.6
  Placebo + PIO 15 mg + MET                            130              54.1 ± 9.5                                          46.9                 31.3 ± 5.0      5.7 ± 4.8   8.5 ± 0.7                                  
  Placebo + PIO 30 mg + MET                            129              56.1 ± 9.4                                          48.8                 31.4 ± 5.4      7.6 ± 7.1   8.5 ± 0.7                                  
  Placebo + PIO 45 mg + MET                            129              54.5 ± 9.7                                          41.1                 30.7 ± 4.7      5.7 ± 4.2   8.5 ± 0.7                                  
  Derosa, 2012                                         12 months        Placebo + MET                                       87                   54.8 ± 7.9      51          28.9 ± 2.0           5.4 ± 2.3             8.0 ± 0.7
  Derosa, 2010                                         12 months        Placebo + PIO/glimepiride                           /                    /               /           /                    /                     /
  Derosa, 2012                                         12 months        Placebo + MET                                       83                   52.4 ± 7.1      51.8        27.8 ± 1.4           6.3 ± 3.9             8.2 ± 0.7
  Dobs, 2013                                           18 weeks         Placebo + MET + RSG                                 92                   54.8 ± 9.5      60          30.8 ± 5.6           9.4 ± 6.8             8.7 ± 1.0
  Fonseca, 2007                                        24 weeks         Placebo + ins                                       152                  58.9 ± 10.8     54.6        32.9 ± 5.9           14.9 ± 8.4            8.4 ± 1.1
  Forst, 2010                                          12 weeks         Placebo                                             71                   60.1 ± 8.1      62          32.2 ± 4.2           6.2 ± 5.1             8.4 ± 0.7
  Garber, 2007                                         24 weeks         Placebo + PIO                                       138                  54.8 ± 10.6     50.7        32.3 ± 5.8           4.8 ± 4.6             8.7 ± 1.2
  Garber, 2008                                         24 weeks         Placebo + SU                                        144                  57.9 ± 10.5     58.3        31.0 ± 5.5           7.8 ± 5.8             8.5 ± 1.0
  Goldstein, 2007                                      24 weeks         Placebo + MET 500 mg bid                            178                  /               /           /                    /                     8.90 ± 1.00
                                                                        Placebo + MET 1000 mg bid                           177                  /               /           /                    /                     8.68 ± 0.91
  Gomis, 2011                                          24 weeks         Placebo + PIO                                       130                  57.1 ± 10.1     65.4        29.7 ± 4.8           /                     8.58 ± 0.08
  Goodman, 2009                                        24 weeks         Placebo + MET                                       122                  54.5 ± 9.7      67.2        31.7 ± 4.3           /                     8.7 ± 1.1
                                                                                                                                                                                                                        
  **DPP-4 inhibitor versus placebo, add-on therapy**                                                                                                                                                                    
                                                                                                                                                                                                                        
  Haak, 2012                                           24 weeks         Placebo + MET 500 mg bid                            144                  52.9 ± 10.4     56.9        28.9 ± 4.8           /                     8.7 ± 0.9
                                                                        Placebo + MET 1000 mg bid                           147                  55.2 ± 10.6     53.1        29.5 ± 5.3           /                     8.5 ± 0.9
  Hermansen, 2007                                      24 weeks         Placebo + glimepiride/placebo + glimepiride + MET   219                  56.5 ± 9.6      53.4        30.7 ± 6.3           9.3 ± 6.8             8.34 ± 0.74
  Hollander, 2009                                      24 weeks         Placebo + TZD                                       184                  54.0 ± 10.1     46.2        30.3 ± 5.8           5.1 ± 5.4             8.2 ± 1.1
  Jadzinsky, 2009                                      24 weeks         Placebo + MET                                       328                  51.8 ± 10.7     49.7        30.2 ± 4.9           1.7 ± 3.1             9.4 ± 1.3
  Kothny, 2012                                         52 weeks         Placebo                                             89                   69.3 ± 7.2      61.8        30.1 ± 5.0           /                     7.9 ± 1.0
                                                                        Placebo                                             64                   65.4 ± 10.5     51.6        30.0 ± 4.7           /                     7.5 ± 1.1
  Lukashevich, 2014                                    24 weeks         Placebo + MET + glimepiride                         160                  55.0 ± 11.1     45%         28.0 ± 4.5           7.5 ± 6.1             8.8 ± 0.9
  Nauck, 2009                                          26 weeks         Placebo + MET                                       104                  56 ± 11         48          32 ± 6               6 ± 5                 8.0 ± 0.9
  Nowicki, 2011                                        12 weeks         Placebo + ins/OADs                                  85                   66.2 ± 9.1      48.2        30.2 ± 6.8           18.2 ± 8.5            8.1 ± 1.1
  Pratley, 2009                                        24 weeks         Placebo + PIO                                       97                   55.2 ± 10.8     54.6        33.2 ± 6.2           /                     8.0 ± 0.8
  Raz, 2008                                            18 weeks         Placebo + MET                                       94                   56.1 ± 9.5      41.5        30.4 ± 5.3           7.3 ± 5.3             9.1 ± 0.8
  Rosenstock, 2006                                     24 weeks         Placebo + PIO                                       178                  56.9 ± 11.1     57.9        31.0 ± 5.0           6.1 ± 5.7             8.0 ± 0.8
  Ross, 2012                                           12 weeks         Placebo + MET                                       43                   59.9 ± 10.7     47.7        28.7 ± 5.5           /                     7.92 ± 0.74
  Scott, 2008                                          18 weeks         Placebo + MET                                       92                   55.3 ± 9.3      59          30.0 ± 4.5           5.4 ± 3.7             7.7 ± 0.9
  Taskinen, 2011                                       24 weeks         Placebo + MET                                       523                  56.6 ± 10.9     57          30.05 ± 5.01         /                     8.02 ± 0.88
  Vilsbøll, 2010                                       24 weeks         Placebo + ins                                       319                  57.2 ± 9.3      53          31 ± 5               12 ± 6                8.6 ± 0.9
                                                                                                                                                                                                                        
  **SGLT2i versus placebo, monotherapy**                                                                                                                                                                                
                                                                                                                                                                                                                        
  Bailey, 2012                                         24 weeks         Placebo                                             68                   53.5 ± 11.08    54.4        32.47 ± 4.91         1.1 ± 1.95            7.8 ± 1.12
  Bailey, 2015                                         102 weeks        Placebo                                             75                   52.7 ± 10.3     41.3        /                    2.1 ± 3.1             7.84 ± 0.87
  Ferrannini, 2010                                     24 weeks         Placebo                                             75                   52.7 ± 10.3     41.3        32.3 ± 5.5           /                     7.84 ± 0.87
  Ferrannini, 2013                                     12 weeks         Placebo                                             82                   58              54.9        28.8                 /                     7.8 ± 0.8
  Fonseca, 2013                                        12 weeks         Placebo                                             69                   53.4 ± 9.7      46.4        30.9 ± 5.5           4.64 ± 5.93           7.84 ± 0.78
  Inagaki, 2013                                        12 weeks         Placebo                                             75                   57.7 ± 11.0     72.0        26.41 ± 4.34         /                     7.99 ± 0.77
  List, 2009                                           12 weeks         Placebo                                             54                   53 ± 11         56          32 ± 5               /                     7.9 ± 0.9
  Stenlöf, 2013                                        26 weeks         Placebo                                             192                  55.7 ± 10.9     45.8        31.8 ± 6.2           4.2 ± 4.1             8.0 ± 1.0
                                                                                                                                                                                                                        
  **SGLT2i versus placebo, add-on therapy**                                                                                                                                                                             
                                                                                                                                                                                                                        
  Bailey, 2010                                         24 weeks         Placebo + MET                                       137                  53.7 ± 10.3     55          31.8 ± 5.3           5.8 ± 5.1             8.11 ± 0.96
  Bailey, 2013                                         102 weeks        Placebo + MET                                       137                  /               /           /                    /                     8.12 ± 0.96
  Barnett, 2014                                        52 weeks         Placebo (CKD, 2)                                    95                   62.6 ± 8.1      58.9        30.8 ± 5.6           /                     8.09 ± 0.80
  Placebo (CKD, 3)                                     187              65.1 ± 8.2                                          56.7                 30.3 ± 5.3      /           8.09 ± 0.80                                
  Placebo (CKD, 4)                                     37               62.9 ± 11.9                                         51.4                 31.8 ± 6.0      /           8.16 ± 0.99                                
  Bode, 2015                                           104 weeks                                                                                                                                                        
  Bolinder, 2012                                       24 weeks         Placebo + MET                                       91                   60.8 ± 6.9      59.2        31.7 ± 3.9           5.5 ± 5.3             7.16 ± 0.53
  Cefalu, 2015                                         52 weeks         Placebo + OAD/ins                                   459                  63.0 ± 7.7      68.6        32.9 ± 6.1           12.3 ± 8.2            8.08 ± 0.80
  Draeger, 2015                                        16 weeks         Placebo + MET                                       101                  58.5 ± 9.4      46.5        31.74 ± 4.69         5.53 ± 4.23           7.94 ± 0.85
  Forst, 2014                                          26 weeks         Placebo + MET + PIO                                 115                  58.3 ± 9.6      66.1        32.5 ± 6.4           10.1 ± 6.6            8.0 ± 1.0
  Häring, 2015                                         76 weeks         Placebo + MET + SU                                  225                  56.9 ± 9.2      49.8        27.9 ± 4.9           /                     8.1 ± 0.8
  Hakjadj, 2016                                        24 weeks                                                                                                                                                         
  Häring, 2013                                         24 weeks         Placebo + MET + SU                                  225                  56.9 ± 9.2      50          27.9 ± 4.9           /                     8.15 ± 0.83
  Häring, 2014                                         24 weeks         Placebo + MET                                       207                  56.0 ± 9.7      56          28.7 ± 5.2           /                     7.90 ± 0.88
  Henry, 2012                                          24 weeks         Dapagliflozin 5 mg/d + placebo                      203                  52.3 ± 10.2     45.3        /                    1.6 ± 3.1             9.1 ± 1.4
  Placebo + MET                                        201              51.8 ± 9.8                                          47.3                 /               1.6 ± 2.6   9.2 ± 1.3                                  
  Dapagliflozin 10 mg/d + placebo                      219              51.1 ± 11.5                                         47.9                 /               2.1 ± 3.8   9.1 ± 1.3                                  
  Placebo + MET                                        208              52.7 ± 10.4                                         46.6                 /               1.9 ± 4.0   9.1 ± 1.3                                  
  Kovacs, 2014                                         24 weeks         Placebo + PIO + MET                                 165                  54.6 ± 10.5     44.2        29.3 ± 5.4           /                     8.2 ± 0.92
  Lavalle-González, 2013                               26 weeks         Placebo + MET                                       183                  55.3 ± 9.8      51.4        31.1 ± 6.1           6.8 ± 5.3             8.0 ± 0.9
                                                                                                                                                                                                                        
  **SGLT2i versus placebo, add-on therapy**                                                                                                                                                                             
                                                                                                                                                                                                                        
  Leiter, 2014                                         24 weeks         Placebo                                             482                  63.6 ± 7.0      67.0        32.7 ± 5.7           13.0 ± 8.4            8.1 ± 0.8
  Ljunggren, 2012                                      50 weeks         Placebo + MET                                       91                   60.8 ± 6.9      56          31.7 ± 3.9           5.5 ± 5.3             7.16 ± 0.53
  Mathieu, 2015                                        24 weeks         Placebo + MET                                       160                  55.06 ± 9.6     47.5        32.26 ± 5.3          8.06 ± 6.6            8.176 ± 0.98
  Matthaei, 2015                                       24 weeks         Placebo + MET + SU                                  109                  60.9 ± 9.2      55.6        32 ± 4.6             9.6 ± 6.2             8.24 ± 0.87
  Merker, 2015                                         76 weeks         Placebo + MET                                       207                  56.0 ± 9.7      56          28.7 ± 5.2           /                     7.9 ± 0.9
  Neal, 2015                                           18 weeks         Placebo + ins                                       636                  63              66          33.1 ± 6.5           16.0 ± 7.8            8.3 ± 0.9
                                                       52 weeks         Placebo + ins                                       639                  63              66          33.1 ± 6.5           16.0 ± 7.8            8.3 ± 0.9
  Rosenstock, 2012                                     12 weeks         Placebo + MET                                       65                   53.3 ± 7.8      48          30.6 ± 4.6           6.4 ± 5.0             7.75 ± 0.83
  Rosenstock, 2012                                     48 weeks         Placebo + PIO                                       139                  53.5 ± 11.4     51.1        /                    5.07 ± 5.05           8.34 ± 1.00
  Rosenstock, 2014                                     52 weeks         Placebo + ins                                       188                  55.3 ± 10.1     40          34.7 ± 4.3           /                     8.33 ± 0.72
  Rosenstock, 2015                                     24 weeks                                                                                                                                                         
  Ross, 2015                                           16 weeks         Placebo + MET                                       207                  /               /           /                    /                     7.69 ± 0.07
  Strojek, 2011                                        24 weeks         Placebo + glimepiride 4 mg/d                        145                  60.3 ± 10.16    49          /                    7.4 ± 5.7             8.15 ± 0.74
  Wilding, 2009                                        12 weeks         Placebo + ins                                       23                   58.4 ± 6.5      69.6        34.8 ± 4.6           13.8 ± 7.3            8.4 ± 0.9
  Wilding, 2012                                        48 weeks         Placebo + ins                                       193                  58.8 ± 8.6      49.2        33.1 ± 5.9           13.5 ± 7.3            8.47 ± 0.77
  Wilding, 2013                                        12 weeks         Placebo + MET                                       66                   57.3 ± 8.6      54.5        32.0 ± 4.8           5.7 ± 3.2             7.68 ± 0.60
  Yale, 2013                                           26 weeks         Placebo                                             90                   68.2 ± 8.4      63.3        33.1 ± 6.5           16.4 ± 10.1           8.0 ± 0.9
                                                                                                                                                                                                                        
  **GLP-1RA versus placebo, monotherapy**                                                                                                                                                                               
                                                                                                                                                                                                                        
  Buse, 2004                                           30 weeks         Placebo                                             123                  55 ± 11         62.6        34 ± 5               5.7 ± 4.7             8.7 ± 1.2
  Fonseca, 2012                                        12 weeks         Placebo                                             122                  54.1 ± 11.0     49.2        31.8 ± 6.7           1.4                   8.07 ± 0.9
  Grunberger G, 2012                                   12 weeks         Placebo                                             32                   55.0 ± 9.3      56.3        32.1 ± 5.2           3.9 ± 4.7             7.4 ± 0.6
  Hollander P, 2013                                    24 weeks         Placebo                                             143                  54 ± 10         61          36.5 ± 4.8           4.9 ± 4.1             7.55 ± 0.84
  Madsbad, 2004                                        12 weeks         Placebo                                             29                   57 ± 9.4        69          30.3 ± 4.2           3.8 ± 3.4             7.8 ± 0.9
  Moretto, 2008                                        24 weeks         Placebo                                             77                   53 ± 9          55          32 ± 5               1 ± 2                 7.8 ± 0.9
  Raz I, 2012                                          24 weeks         Placebo                                             123                  55.8 ± 8.5      37          32.1 ± 5.3           2.3 ± 1.9             7.6 ± 1.0
  Rosenstock, 2009                                     16 weeks         Placebo                                             50                   /               /           /                    /                     7.8 ± 0.9
  Terauchi, 2014                                       12 weeks         Placebo                                             37                   51.7 ± 9.7      78.4        27.4 ± 4.5           4.7 ± 4.5             8.0 ± 0.6
  Vilsbøll, 2007                                       14 weeks         Placebo                                             40                   57.7 ± 8.2      47.5        30.4 ± 4.0           5                     8.2 ± 0.7
  Vilsbøll, 2008                                       14 weeks         Placebo                                             10                   55.4 ± 6.7      80          30.3 ± 4.3           1.8 ± 0.8             8.1 ± 0.3
                                                                                                                                                                                                                        
  **GLP-1RA versus placebo, add-on therapy**                                                                                                                                                                            
                                                                                                                                                                                                                        
  Ahrén B, 2013                                        24 weeks         Placebo + MET                                       170                  55.0 ± 9.4      47.6        33.1 ± 6.5           5.9 ± 4.7             8.1 ± 0.9
  Apovian, 2010                                        24 weeks         Placebo + MET                                       51                   55.0 ± 7.9      39          33.6 ± 4.6           3.9 ± 3.2             7.2 ± 0.5
                                                                        MET + SU + placebo                                  36                   55.1 ± 9.9      31          34.3 ± 4.0           7.6 ± 6.9             7.9 ± 0.9
                                                                        Exenatide + placebo                                 11                   55.3 ± 11.3     54          33.8 ± 4.3           4.3 ± 2.8             7.7 ± 1.1
  Bergenstal, 2012                                     24 weeks         Placebo + MET                                       90                   56.1 ± 10.1     52          32.5 ± 5.5           5.5 ± 3.9             8.03 ± 0.83
  Bolli GB, 2014                                       24 weeks         Placebo + MET                                       160                  58.2 ± 9.8      45          32.4 ± 5.5           6.2 ± 4.7             8.0 ± 0.8
  Buse, 2004                                           30 weeks         Placebo + SU                                        123                  55 ± 11         62.6        34 ± 5               5.7 ± 4.7             8.7 ± 1.2
  Davies, 2015                                         56 weeks         Placebo                                             211                  54.7 ± 9.8      45.8        37.4 ± 7.1           6.7 ± 5.07            7.9 ± 0.8
  DeFronzo, 2005                                       30 weeks         Placebo + NET                                       113                  54 ± 9          59.3        34 ± 6               6.6 ± 6.1             8.2 ± 1.0
  Home, 2015                                           156 weeks        Placebo + MET + glimepiride                         115                  55.7 ± 9.6      60.9        31.8 ± 4.9           9.3 ± 6.1             8.26 ± 0.98
  Kendall, 2005                                        30 weeks         Placebo + MET + SU                                  247                  56 ± 10         55.9        34 ± 5               9.4 ± 6.2             8.5 ± 1.0
  Lind, 2015                                           24 weeks                                                                                                                                                         
  Marre, 2009                                          26 weeks         Placebo + glimepiride 2--4 mg/d                     114                  54.7 ± 10.0     47          30.3 ± 5.4           6.5                   8.4 ± 1.0
  Nauck, 2009                                          26 weeks         Placebo + MET                                       121                  56 ± 9          60          31.6 ± 4.4           8 ± 6                 8.4 ± 1.1
  Pinget M, 2013                                       24 weeks         Placebo + PIO ± MET                                 161                  55.3 ± 9.5      51          34.4 ± 7.0           8.1 ± 5.6             8.1 ± 0.8
  Ratner, 2010                                         13 weeks         Placebo                                             109                  56.3 ± 9.2      56          31.7 ± 4.2           7.1 ± 5.4             7.53 ± 0.6
  Reusch, 2014                                         52 weeks         Placebo + PIO ± MET                                 151                  54.9 ± 9.40     58.3        34.7 ± 5.6           7.9 ± 6.1             8.1 ± 0.9
                                                                                                                                                                                                                        
  **GLP-1RA versus placebo, add-on therapy**                                                                                                                                                                            
                                                                                                                                                                                                                        
  Riddle MC, 2013                                      24 weeks         Placebo + ins + MET ± TZD                           223                  56 ± 10         51          31.7 ± 6.0           8.7 ± 5.8             7.6 ± 0.5
  Riddle MC, 2013-1                                    24 weeks         Placebo + ins ± MET                                 167                  57 ± 10         49          32.6 ± 6.3           12.4 ± 6.3            8.4 ± 0.8
  Russell-Jones, 2009                                  26 weeks         Placebo + MET + glimepiride                         114                  57.5 ± 9.6      49          31.3 ± 5.0           9.4 ± 6.2             8.3 ± 0.9
  Skrivanek, 2014                                      52 weeks         Placebo + MET                                       38                   53 ± 11         32          32 ± 4               7 ± 6                 8.1 ± 1.1
  Umpierrez, 2011                                      16 weeks         Placebo                                             66                   56 ± 12         44          33.9 ± 4.3           7.5 ± 5.4             8.05 ± 0.8
  Zinman, 2007                                         16 weeks         Placebo + TZD ± MET                                 112                  53.7 ± 10.2     57.1        34.0 ± 5.0           8.2 ± 5.8             7.9 ± 0.8
  Zinman, 2009                                         26 weeks         Placebo + MET 1 g bid + RSG 4 mg bid                177                  55 ± 10         62          33.9 ± 5.2           9 ± 6                 8.4 ± 1.2

Data are given as the mean ± SD. BMI: Body mass index; DM: Diabetes mellitus; HbA1c: Glycosylated hemoglobin; SU: Sulfonylurea; MET: Metformin; TZD: Thiazolidinediones; AGI: Alpha glucosidase inhibitors; DPP-4: Dipeptidyl peptidase-4 inhibitors; SGLT2i: Sodium-glucose cotransporter 2 inhibitors; GLP-1RA: Glucagon-like peptide-1 analogs; CKD: Chronic kidney disease; SD: Standard deviation; PIO: Pioglitazone; PBO: Placebo; ASP: Insulin Aspart; OADs: Oral hypoglycemic drugs; RSG: Rosiglitazone; ins: Insulin.

Baseline characteristics of the patients received placebo treatment in different studies are shown in [Table 1](#T3){ref-type="table"}. Baseline BMI was significantly different between Asian and Caucasians in the treatment of AGIs, TZDs, DPP-4i, SGLT2i, and GLP-1RAs, but not in the treatment of MET. Other characteristics such as baseline age, gender, duration of diabetes, and baseline HbA1c were comparable between Asian and Caucasian populations in most kinds of antidiabetic treatment.

###### 

Baseline characteristics of patients receiving placebo treatment compared between Asian population and Caucasian population in each kind of antidiabetic agents

  Variables                 Asian (*n*=63)   Caucasian (*n*=262)   *t*       *P*
  ------------------------- ---------------- --------------------- --------- ---------
  SU                                                                         
   Number of studies        0                22                              
   Age (years)              /                57.1 ± 4.3            /         /
   Male (%)                 /                42                    /         /
   Baseline BMI (kg/m^2^)   /                30.1 ± 2.7            /         /
   DM duration (years)      /                6.6 ± 3.1             /         /
   Baseline HbA1c (%)       /                8.60 ± 1.12           /         /
  MET                                                                        
   Number of studies        1                16                              
   Age (years)              56.0 ± 2.8       57.0 ± 2.3            −0.580    0.568
   Male (%)                 44               42                    −0.206    0.839
   Baseline BMI (kg/m^2^)   30.0 ± 1.4       30.5 ± 2.0            −0.334    0.742
   DM duration (years)      3.0 ± 0.0        7.4 ± 3.2             −1.912    0.077
   Baseline HbA1c (%)       8.00 ± 0.00      8.61 ± 1.40           −0.601    0.554
  AGI                                                                        
   Number of studies        8                35                              
   Age (years)              55.6 ± 3.7       59.4 ± 4.1            −2.353    0.025
   Male (%)                 54               43                    −1.786    0.086
   Baseline BMI (kg/m^2^)   24.0 ± 0.0       29.6 ± 2.4            −3.279    0.001
   DM duration (years)      8.2 ± 5.2        6.4 ± 2.9             1.119     0.273
   Baseline HbA1c (%)       9.13 ± 0.84      8.16 ± 1.24           2.069     0.046
  TZD                                                                        
   Number of studies        12               72                              
   Age (years)              55.5 ± 5.0       57.7 ± 3.5            −1.744    0.086
   Male (%)                 44               41                    −0.680    0.499
   Baseline BMI (kg/m^2^)   24.2 ± 1.8       31.1 ± 2.2            −8.798    \<0.001
   DM duration (years)      7.2 ± 3.0        7.0 ± 3.4             0.129     0.898
   Baseline HbA1c (%)       8.64 ± 1.12      8.24 ± 1.05           1.138     0.262
  DPP-4i                                                                     
   Number of studies        23               46                              
   Age (years)              56.6 ± 3.3       57.1 ± 5.0            −0.423    0.673
   Male (%)                 40               46                    2.945     0.004
   Baseline BMI (kg/m^2^)   25.3 ± 1.1       30.6 ± 1.5            −15.516   \<0.001
   DM duration (years)      5.9 ± 2.8        6.4 ± 3.7             −0.551    0.584
   Baseline HbA1c (%)       8.24 ± 0.78      8.22 ± 0.46           0.127     0.899
  SGLT2i                                                                     
   Number of studies        11               38                              
   Age (years)              56.7 ± 4.1       57.6 ± 4.2            −0.633    0.530
   Male (%)                 37               46                    2.906     0.005
   Baseline BMI (kg/m^2^)   26.9 ± 1.9       31.3 ± 1.9            −6.247    \<0.001
   DM duration (years)      5.9 ± 2.4        7.8 ± 4.8             −1.093    0.282
   Baseline HbA1c (%)       8.00 ± 0.0       8.05 ± 0.4            −0.394    0.695
  GLP-1RA                                                                    
   Number of studies        8                33                              
   Age (years)              56.6 ± 2.7       55.7 ± 1.9            1.122     0.269
   Male (%)                 41               48                    1.541     0.131
   Baseline BMI (kg/m^2^)   26.8 ± 3.6       33.0 ± 1.8            −7.177    \<0.001
   DM duration (years)      8.1 ± 3.3        6.6 ± 3.2             1.233     0.225
   Baseline HbA1c (%)       8.22 ± 0.44      8.00 ± 0.35           1.610     0.115

Data are given as the mean ± SD. *P* values indicated the significance of the comparisons between Asian and Caucasian. SU: Sulfonylurea; BMI: Body mass index; DM: Diabetes mellitus; HbA1c: Glycosylated hemoglobin; MET: Metformin; AGI: Alpha glucosidase inhibitor; TZD: Thiazolidinedione; DPP-4i: Dipeptidyl peptidase-4 inhibitor; SGLT2i: Sodium-glucose cotransporter 2 inhibitor; GLP-1RA: Glucagon-like peptide-1 receptor agonist; SD: Standard deviation; /: No reported data.

Methodological quality {#sec2-7}
----------------------

All studies were double-blindly designed with placebo controlled. The heterogeneity was assessed for each hypoglycemic treatment. When the I^2^ \> 50%, the random-effect model was used, and when the I^2^ ≤ 50%, the fixed-effect model was used. The publication bias assessed via visual inspection of the funnel plot suggested no significant risk of publication bias. The risk of bias in each study was evaluated according to the Cochrane instrument in both Asian population and Caucasian population \[Supplementary Figures S1 and S2\].

###### 

Evaluation of the risk of bias of the studies included in Asian population.

###### 

Click here for additional data file.

###### 

Evaluation of the risk of bias of the studies included in Caucasian population.

###### 

Click here for additional data file.

Placebo effect in glycosylated hemoglobin between Asian and Caucasian population in antidiabetic treatment {#sec2-8}
----------------------------------------------------------------------------------------------------------

In SU treatment group, the use of placebo led to a nonsignificant HbA1c change from baseline (MD, 0.187%; 95% *CI*, −0.144--0.518%; *P* = 0.269) in Caucasian population. There was no study in Asian population. In MET treatment group, the placebo effect led to a nonsignificant HbA1c change of 0.127% (95% *CI*, −0.360--0.613%; *P* = 0.610) in Caucasian population and also a nonsignificant HbA1c change of 0.140% (95% *CI*, −1.330--1.611%; *P* = 0.852) in Asian population. In AGI treatment group, the placebo effect resulted in an HbA1c change of 0.014% without significance (95% *CI*, −0.275--0.304%; *P* = 0.923) in Caucasians and resulted in a nonsignificant HbA1c change of −0.070% (95% *CI*, −0.562--0.421%; *P* = 0.779) in Asians. In TZD treatment group, the placebo effect led to a nonsignificant HbA1c change of 0.130% (95% *CI*, −0.174--0.433%; *P* = 0.402) in Caucasians as well as a nonsignificant HbA1c change of −0.036% (95% *CI*, −0.962--0.890%; *P* = 0.939) in Asians. In DPP-4i treatment group, the placebo effect led to a significant decrease in HbA1c (MD, −0.193%; 95% *CI*, −0.311--−0.075%; *P* = 0.001) in Caucasian population and also a significant reduction of HbA1c (MD, −0.162%; 95% *CI*, −0.289--−0.035%; *P* = 0.012) in Asian population. In SGLT2i treatment group, the placebo effect resulted in a significant decrease in HbA1c (MD, −0.230%; 95% *CI*, −0.340--−0.121%; *P* \< 0.001) in Caucasians while it resulted in a nonsignificant HbA1c change of − 0.047% (95% *CI*, −0.543--0.449%; *P* = 0.853) in Asian population. In GLP-1RA treatment group, the placebo effect led to an HbA1c change of −0.172% (95% *CI*, −0.383--0.038%; *P* = 0.109) without significance in Caucasians and also a nonsignificant HbA1c change of −0.214% (95% *CI*, −0.448--0.021%; *P* = 0.074) in Asians \[[Table 2](#T4){ref-type="table"}\]. Comparisons of the placebo effect in HbA1c changes relative to baseline indicated that no significant difference was found between Asian and Caucasian population in MET, AGI, TZD, DPP-4i, SGLT-2i, and GLP-1RA treatment. Since no studies of Asian population in SU treatment, it was concerned lack of evidence for comparing the Asian and Caucasian population in this category \[[Table 2](#T4){ref-type="table"} and Supplementary Figures S3-S15\].

###### 

Placebo effect on HbA1c changes in the antidiabetic treatment between Asian and Caucasian population

  Variables   Asian   Caucasian   Differences^‡^                                                                
  ----------- ------- ----------- ---------------- ------- ------ ---- -------- ---------------- ------- ------ --------
  SU                                                                                                            
   Total      0       /           /                /       /      25   0.187    −0.144--0.518    0.269   77.7   /
   Mono       0       /           /                /       /      11   0.683    0.181--1.185     0.008   61.9   /
   Addon      0       /           /                /       /      14   −0.286   −0.721--0.149    0.197   60.7   /
  MET                                                                                                           
   Total      2       0.140       −1.330--1.611    0.852   0.0    23   0.127    −0.360--0.613    0.610   68.3   0.013
   Mono       2       0.140       −1.330--1.611    0.852   0.0    15   0.404    −0.112--0.919    0.125   85.3   −0.264
   Addon      0       /           /                /       /      8    −0.375   −1.374--0.624    0.462   70.9   /
  AGI                                                                                                           
   Total      8       −0.070      −0.562--0.421    0.779   0.0    35   0.014    −0.275--0.304    0.923   92.4   −0.084
   Mono       2       −0.301      −0.921--0.319    0.341   0.0    20   0.128    −0.285--0.541    0.545   92.4   −0.429
   Addon      6       −0.014      −0.607--0.578    0.962   0.0    15   −0.066   −0.464--0.332    0.746   88.3   0.052
  TZD                                                                                                           
   Total      11      −0.036      −0.962--0.890    0.939   0.0    66   0.130    −0.174--0.433    0.402   79.3   −0.166
   Mono       2       0.203       −2.328--2.735    0.875   0.0    33   0.403    −0.091--0.898    0.110   76.7   −0.200
   Addon      9       −0.105      −1.048--0.838    0.827   0.0    33   −0.016   −0.399--0.367    0.934   82.2   −0.089
  DPP-4i                                                                                                        
   Total      28      −0.162      −0.289--−0.035   0.012   88.9   54   −0.193   −0.311--−0.075   0.001   94.2   0.031
   Mono       10      −0.041      −0.191--0.108    0.588   91.8   16   0.091    −0.128--0.311    0.415   62.6   −0.132
   Addon      18      −0.211      −0.379--−0.044   0.013   80.0   38   −0.288   −0.427--−0.149   0.000   95.3   0.077
  SGLT2i                                                                                                        
   Total      10      −0.047      −0.543--0.449    0.853   87.2   43   −0.230   −0.340--−0.121   0.000   88.5   0.183
   Mono       9       0.053       −0.398--0.504    0.818   79.5   8    0.033    −0.565--0.632    0.913   42.4   0.020
   Addon      1       /           /                /       /      35   −0.257   −0.361--−0.154   0.000   90.6   /
  GLP-1RA                                                                                                       
   Total      9       −0.214      −0.448--0.021    0.074   81.3   34   −0.172   −0.383--0.038    0.109   72.1   −0.042
   Mono       3       0.048       −0.670--0.765    0.897   18.5   9    −0.091   −0.502--0.321    0.666   0.0    0.139
   Addon      6       −0.269      −0.509--−0.029   0.028   85.0   25   −0.188   −0.427--0.050    0.122   79.0   −0.081

\**P* value represented the significance of placebo effect on HbA1c changes from baseline in Asian population; ^†^*P* value represented the significance of placebo effect on HbA1c changes from baseline in Caucasian population. ^‡^All differences of HbA1c changes between Asian and Caucasian populations were without significance. MD: Mean difference; *CI*: Confidence interval; SU: Sulfonylurea; MET: Metformin; AGI: Alpha glucosidase inhibitor; TZD: Thiazolidinedione; DPP-4i: Dipeptidyl peptidase-4 inhibitor; SGLT2i: Sodium-glucose cotransporter 2 inhibitor; GLP-1RA: Glucagon-like peptide-1 receptor agonist; Mono: Monotherapy; Addon: Add-on therapy; *n*: Number of treatment arms included; /: No reported data.
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Placebo effect on HbA1c changes in sulfonylurea treatment group in Caucasian population.
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Click here for additional data file.
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Placebo effect on HbA1c changes in metformin treatment group in Asian population.
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Click here for additional data file.
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Placebo effect on HbA1c changes in metformin treatment group in Caucasian population.
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Click here for additional data file.
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Placebo effect on HbA1c changes in alpha glucosidase inhibitors treatment group in Asian population.
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Click here for additional data file.
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Placebo effect on HbA1c changes in alpha glucosidase inhibitors treatment group in Caucasian population.
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Click here for additional data file.
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Placebo effect on HbA1c changes in thiazolidinediones treatment group in Asian population.
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Click here for additional data file.
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Placebo effect on HbA1c changes in thiazolidinediones treatment group in Caucasian population.
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Click here for additional data file.
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Placebo effect on HbA1c changes in DPP-4 inhibitors treatment group in Asian population.

###### 

Click here for additional data file.
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Placebo effect on HbA1c changes in DPP-4 inhibitors treatment group in Caucatian population.
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Click here for additional data file.
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Placebo effect on HbA1c changes in sodium-glucose cotransporter 2 inhibitors treatment group in Asian population.

###### 

Click here for additional data file.
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Placebo effect on HbA1c changes in sodium-glucose cotransporter 2 inhibitors treatment group in Caucatian population.
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Click here for additional data file.
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Placebo effect on HbA1c changes in glucagon-like peptide-1 analogs treatment group in Asian population.
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Click here for additional data file.
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Placebo effect on HbA1c changes in glucagon-like peptide-1 analogs treatment group in Caucasian population.

###### 

Click here for additional data file.

Placebo effect in body weight between Asian and Caucasian population in antidiabetic treatment {#sec2-9}
----------------------------------------------------------------------------------------------

In SU treatment group, the placebo effect resulted in a significant weight decrease (MD, −0.833 kg; 95% *CI*, −1.423--−0.243 kg; *P* = 0.006) in Caucasian population. No data were found with placebo effect in Asians. In MET treatment group, the placebo effect resulted in a nonsignificant weight change of −0.686 kg (95% *CI*, −2.823--1.451 kg; *P* = 0.529) in Caucasian population. No data were found with placebo effect in Asian population. In AGI treatment group, the placebo effect resulted in a nonsignificant weight change of −0.594 kg (95% *CI*, −1.607--0.420 kg; *P* = 0.251) in Caucasians and also a nonsignificant body weight change of 0.145 kg (95% *CI*, −1.543--1.834 kg; *P* = 0.866) in Asians. In TZD treatment group, the placebo effect led to a weight change of 0.018 kg without significance (95% *CI*, −0.945--0.982 kg; *P* = 0.970) in Caucasians and also a nonsignificant body weight change of −0.348 kg (95% *CI*, −1.494--0.797 kg; *P* = 0.551) in Asians. In DPP-4i treatment group, the placebo effect led to a weight change of −0.058 kg without significance (95% *CI*, −0.407--0.290 kg; *P* = 0.743) in Caucasian population and a nonsignificant body weight change of −0.345 kg (95% *CI*, −0.854--0.164 kg; *P* = 0.184) in Asian population. In SGLT2i treatment group, the placebo treatment led to a weight change of −0.512 kg without significance (95% *CI*, −2.882--1.859 kg; *P* = 0.672) in Caucasians and also a nonsignificant body weight change of −0.399 kg (95% *CI*, −1.286--0.488 kg; *P* = 0.378) in Asian population. In GLP-1RA treatment group, weight change in placebo effect was −0.953 kg with significance (95% *CI*, −1.626--−0.280 kg; *P* = 0.006) in Caucasians, and in Asians, the placebo effect was associated with a significant body weight reduction (MD, −0.612 kg; 95% *CI*, −0.884--−0.339 kg; *P* \< 0.001). Comparisons of the placebo effect in body weight changes from baseline indicated that no significant difference was found between Asian and Caucasian population in AGI, TZD, DPP-4i, SGLT-2i, and GLP-1RA treatment. Since no studies of Asian population in SU and MET treatment, it was concerned lack of evidence for comparing the Asian and Caucasian population in those treatments \[[Table 3](#T5){ref-type="table"} and Supplementary Figures S16-S27\].

###### 

Placebo effect on body weight changes in the antidiabetic treatment between Asian and Caucasian population

  Variables   Asian   Caucasian   Differences^‡^                                                                     
  ----------- ------- ----------- ---------------- --------- ------ ---- -------- ----------------- --------- ------ --------
  SU                                                                                                                 
   Total      0       /           /                /         /      10   −0.833   −1.423--−0.243    0.006     99.5   /
   Mono       0       /           /                /         /      6    −0.947   −1.810--−0.084    0.032     99.8   /
   Addon      0       /           /                /         /      4    −0.647   −1.301--0.007     0.053     77.4   /
  MET                                                                                                                
   Total      0       /           /                /         /      8    −0.686   −2.823--1.451     0.529     0.0    /
   Mono       0       /           /                /         /      6    −0.950   −3.624--1.723     0.486     0.0    /
   Addon      0       /           /                /         /      2    0.346    −0.597--1.288     0.472     88.9   /
  AGI                                                                                                                
   Total      3       0.145       −1.543--1.834    0.866     0.0    12   −0.594   −1.607--0.420     0.251     0.0    0.739
   Mono       1       /           /                /         /      9    −0.699   −1.733--0.335     0.185     0.0    /
   Addon      2       0.136       −2.341--2.612    0.914     0.0    3    −0.330   −2.759--2.099     0.790     0.0    0.466
  TZD                                                                                                                
   Total      4       −0.348      −1.494--0.797    0.551     0.0    19   0.018    −0.945--0.982     0.970     67.4   −0.366
   Mono       1       /           /                /         /      7    −0.582   −1.161--−0.003    0.049     73.4   /
   Addon      3       −0.322      −1.567--0.923    0.612     0.0    12   0.122    −1.003--1.247     0.832     71.3   −0.444
  DPP-4i                                                                                                             
   Total      13      −0.345      −0.854--0.164    0.184     45.1   34   −0.058   −0.407--0.290     0.743     85.9   −0.287
   Mono       6       −0.468      −0.989--0.054    0.079     29.3   10   −0.304   −0.720--0.112     0.152     87.7   −0.164
   Addon      7       −0.242      −1.070--0.587    0.567     30.4   24   0.030    −0.419--0.479     0.896     85.4   −0.272
  SGLT2i                                                                                                             
   Total      10      −0.399      −1.286--0.488    0.378     9.3    41   −0.512   −2.882--1.859     0.672     69.5   0.113
   Mono       9       −0.375      −1.447--0.696    0.492     33.3   8    −0.975   −12.230--10.279   0.865     0.0    0.600
   Addon      1       /           /                /         /      33   −0.453   −2.711--1.805     0.694     74.9   /
  GLP-1RA                                                                                                            
   Total      8       −0.612      −0.884--−0.339   \<0.001   38.8   28   −0.953   −1.626--−0.280    0.006     83.2   0.341
   Mono       3       −0.767      −1.270--−0.264   0.003     0.0    7    −1.388   −1.804--−0.973    \<0.001   85.3   0.621
   Addon      5       −0.570      −0.888--−0.252   \<0.001   63.8   21   −0.882   −1.662--−0.102    0.027     82.3   0.312

\**P* value represented the significance of placebo effect on body weight changes from baseline in Asian population; ^†^*P* value represented the significance of placebo effect on body weight changes from baseline in Caucasian population. ^‡^All differences of body weight changes between Asian and Caucasian populations were without significance. MD: Mean difference; *CI*: Confidence interval; SU: Sulfonylurea; MET: Metformin; AGI: Alpha glucosidase inhibitor; TZD: Thiazolidinedione; DPP-4i: Dipeptidyl peptidase-4 inhibitor; SGLT2i: Sodium-glucose cotransporter 2 inhibitor; GLP-1RA: Glucagon-like peptide-1 receptor agonist; Mono: Monotherapy; Addon: Add-on therapy; *n*: Number of treatment arms included; /: No reported data.
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Placebo effect on weight changes in sulfonylurea treatment group in Caucasian population.
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Click here for additional data file.
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Placebo effect on weight changes in metformin treatment group in Caucatian population.
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Click here for additional data file.
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Placebo effect on weight changes in alpha glucosidase inhibitors treatment group in Asian population.
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Click here for additional data file.

###### 

Placebo effect on weight changes in alpha glucosidase inhibitors treatment group in Caucasian population.
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Click here for additional data file.
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Placebo effect on weight changes in thiazolidinediones treatment group in Asian population.
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Click here for additional data file.
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Placebo effect on weight changes in thiazolidinediones treatment group in Caucasian population.
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Click here for additional data file.
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Placebo effect on weight changes in DPP-4 inhibitors treatment group in Asian population.

###### 

Click here for additional data file.
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Placebo effect on weight changes in DPP-4 inhibitors treatment group in Caucasian population.
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Click here for additional data file.
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Placebo effect on weight changes in sodium-glucose cotransporter 2 inhibitors treatment group in Asian population.
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Click here for additional data file.
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Placebo effect on weight changes in sodium-glucose cotransporter 2 inhibitors treatment group in Caucasian population.
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Click here for additional data file.
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Placebo effect on weight changes in glucagon-like peptide-1 analogs treatment group in Asian population.
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Click here for additional data file.
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Placebo effect on weight changes in glucagon-like peptide-1 analogs treatment group in Caucasian population.
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Click here for additional data file.

Associated factors with placebo effect {#sec2-10}
--------------------------------------

Meta-regression analysis indicated that, in each antidiabetic treatment group, the HbA1c changes in placebo treatment were not associated with the baseline age, gender, BMI, baseline HbA1c, DM duration, or study duration, respectively. There was also no association between HbA1c change and weight change from baseline. Meta-regression analysis also suggested that the weight change was not associated with the baseline age, gender, baseline BMI, duration of diabetes, study duration, baseline HbA1c, and the HbA1c changes from baseline in each antidiabetic treatment \[[Supplementary Table S3](#T6){ref-type="table"}\].

###### 

Meta-regression analysis for placebo effect

  Variables                 Asian    Caucasian                                           
  ------------------------- -------- ----------------- ------- -------- ---------------- -------
  SU                                                                                     
   HbA1c change                                                                          
    Total group                                                                          
     Age                    /        /                 /       0.056    −0.014--0.125    0.109
     Sex                    /        /                 /       0.017    −0.001--0.349    0.063
     BMI                    /        /                 /       −0.091   −0.196--0.014    0.083
     Duration of diabetes   /        /                 /       0.015    −0.073--0.104    0.721
     Study duration         /        /                 /       −0.000   −0.009--0.008    0.935
     Baseline HbA1c         /        /                 /       −0.166   −0.393--0.061    0.144
     Baseline weight        /        /                 /       /        /                /
     Weight change          /        /                 /       −0.193   −0.370--−0.017   0.034
  Weight change                                                                          
    Total group                                                                          
     Age                    /        /                 /       −0.417   0.997--0.163     0.142
     Sex                    /        /                 /       −0.056   −0.183--0.072    0.359
     BMI                    /        /                 /       0.426    −0.560--1.412    0.354
     Duration of diabetes   /        /                 /       −0.213   −0.839--0.414    0.467
     Study duration         /        /                 /       −0.010   −0.154--0.135    0.888
     Baseline HbA1c         /        /                 /       −0.065   −2.681--2.550    0.958
     Baseline weight        /        /                 /       0.033    −0.259--0.326    0.801
     HbA1c change           /        /                 /       −2.994   −4.365--−1.624   0.000
  MET                                                                                    
   HbA1c change                                                                          
    Total group                                                                          
     Age                    /        /                 /       −0.075   −0.214--0.064    0.272
     Sex                    /        /                 /       −0.001   −0.021--0.029    0.938
     BMI                    /        /                 /       −0.075   −0.257--0.107    0.395
     Duration of diabetes   /        /                 /       −0.192   −0.341--−0.042   0.016
     Study duration         /        /                 /       0.002    −0.009--0.012    0.761
     Baseline HbA1c         /        /                 /       0.084    −0.141--0.310    0.446
     Baseline weight        /        /                 /       −0.035   −0.096--0.027    0.250
     Weight change          /        /                 /       −0.106   −0.343--0.132    0.356
  Weight change                                                                          
    Total group                                                                          
     Age                    /        /                 /       0.072    −0.230--0.373    0.618
     Sex                    /        /                 /       0.013    −0.035--0.060    0.573
     BMI                    /        /                 /       −0.080   −0.974--0.814    0.849
     Duration of diabetes   /        /                 /       0.335    −0.316--0.985    0.282
     Study duration         /        /                 /       0.006    −0.049--0.062    0.805
     Baseline HbA1c         /        /                 /       0.302    −0.937--1.540    0.609
     Baseline weight        /        /                 /       0.135    −0.044--0.314    0.128
     HbA1c change           /        /                 /       −0.061   −1.257--1.134    0.914
  AGI                                                                                    
   HbA1c change                                                                          
    Total group                                                                          
     Age                    0.004    −0.120--0.127     0.946   0.017    −0.052--0.086    0.607
     Sex                    −0.016   −0.065--0.033     0.450   −0.005   −0.035--0.237    0.700
     BMI                    /        /                 /       −0.019   −0.142--0.104    0.756
     Duration of diabetes   0.025    −0.190--0.240     0.765   −0.108   −0.227--0.010    0.071
     Study duration         −0.017   −0.130--0.095     0.718   0.007    −0.008--0.022    0.356
     Baseline HbA1c         0.130    −0.240--0.500     0.423   −0.301   −0.572--−0.031   0.030
     Baseline weight        /        /                 /       0.017    −0.031--0.066    0.467
     Weight change          1.143    −3--789--6.074    0.424   −0.178   −0.408--0.052    0.121
  Weight change                                                                          
   Total group                                                                           
     Age                    0.104    −1.373--1.581     0.791   0.023    −0.305--0.351    0.881
     Sex                    /        /                 /       0.001    −0.066--0.068    0.978
     BMI                    /        /                 /       −0.055   −0.528--0.418    0.808
     Duration of diabetes   0.671    −38.678--37.336   0.860   0.079    −0.222--0.380    0.576
     Study duration         0.083    −1.578--1.745     0.849   −0.017   −0.074--0.041    0.549
     Baseline HbA1c         0.297    −5.280--5.874     0.840   0.109    −0.876--1.095    0.817
     Baseline weight        /        /                 /       −0.018   −0.092--0.056    0.614
     HbA1c change           0.593    −11.369--12.556   0.851   0.097    −1.807--2.002    0.915
  TZD                                                                                    
   HbA1c change                                                                          
    Total group                                                                          
     Age                    −0.004   −0.073--0.065     0.899   0.026    −0.031--0.084    0.356
     Sex                    −0.001   −0.020--0.019     0.938   0.005    −0.008--0.018    0.472
     BMI                    0.036    −0.182--0.255     0.706   −0.090   −0.186--0.006    0.066
     Duration of diabetes   −0.021   −0.276--0.233     0.826   −0.040   −0.097--0.016    0.158
     Study duration         0.002    −0.058--0.062     0.947   −0.011   −0.027--0.004    0.150
     Baseline HbA1c         −0.056   −0.368--0.256     0.695   0.052    −0.091--0.196    0.468
     Baseline weight        −0.007   −0.241--0.228     0.940   −0.022   −0.054--0.010    0.175
     Weight change          −0.219   −2.345--1.906     0.789   −0.004   −0.150--0.143    0.960
  Weight change                                                                          
    Total group                                                                          
     Age                    0.040    −0.593--0.673     0.868   0.039    −0.178--0.256    0.716
     Sex                    −0.135   −0.237--0.210     0.875   0.006    −0.038--0.050    0.787
     BMI                    −0.114   −1.688--1.460     0.850   −0.332   −0.599--−0.065   0.016
     Duration of diabetes   /        /                 /       −0.018   −0.207--0.171    0.848
     Study duration         −0.012   −0.215--0.191     0.879   −0.059   −0.015--0.041    0.241
     Baseline HbA1c         0.117    −2.087--2.322     0.890   −0.594   −1.080--−0.108   0.018
     Baseline weight        /        /                 /       −0.155   −0.244--−0.065   0.001
      HbA1c change          −0.273   −19.846--19.301   0.971   0.360    −0.770--1.490    0.521
  DPP-4i                                                                                 
   HbA1c change                                                                          
    Total group                                                                          
     Age                    0.046    −0.000--0.092     0.050   0.018    −0.010--0.046    0.198
     Sex                    0.025    0.013--0.037      0.000   0.011    −0.009--−.032    0.269
     BMI                    −0.098   −0.224--0.027     0.118   0.032    −0.072--0.136    0.537
     Duration of diabetes   0.024    −0.037--0.086     0.409   0.007    −0.034--0.049    0.723
     Study duration         −0.044   −0.061--−0.027    0.000   −0.004   −0.018--0.009    0.514
     Baseline HbA1c         −0.060   −0.238--0.118     0.492   −0.418   −0.669--−0.166   0.002
     Baseline weight        −0.030   −0.077--0.017     0.186   0.015    −0.027--0.056    0.476
     Weight change          0.322    −0.046--0.692     0.081   0.039    −0.102--0.179    0.583
  Weight change                                                                          
    Total group                                                                          
     Age                    0.009    −0.061--0.080     0.779   0.035    −0.073--0.144    0.511
     Sex                    −0.010   −0.056--0.037     0.658   0.026    −0.033--0.086    0.376
     BMI                    −0.106   −0.664--0.453     0.690   0.004    −0.307--0.315    0.981
     Duration of diabetes   0.034    −0.058--0.126     0.433   0.109    0.003--0.215     0.044
     Study duration         0.003    −0.052--0.058     0.918   0.029    −0.006--0.065    0.106
     Baseline HbA1c         0.139    −0.496--0.774     0.644   0.558    −0.269--1.386    0.180
     Baseline weight        −0.081   −0.210--0.039     0.157   −0.010   −0.120--0.100    0.850
      HbA1c change          −0.283   −1.316--0.751     0.564   −0.915   −2.651--0.821    0.293
  SGLT2i                                                                                 
   HbA1c change                                                                          
    Total group                                                                          
     Age                    0.055    −0.021--0.131     0.134   0.074    0.038--0.110     0.000
     Sex                    0.013    −0.007--0.033     0.176   0.024    0.004--0.044     0.023
     BMI                    −0.059   −0.179--0.061     0.283   −0.006   −0.091--0.079    0.885
     Duration of diabetes   −0.081   −0.333--0.171     0.462   0.046    0.010--0.083     0.015
     Study duration         0.001    −0.010--0.0112    0.881   0.004    −0.003--0.011    0.270
     Baseline HbA1c         0.264    −0.926--1.454     0.623   −0.793   −1.067--−0.518   0.000
     Baseline weight        /        /                 /       /        /                /
     Weight change          0.589    −0.264--1.442     0.150   /        /                /
  Weight change                                                                          
    Total group                                                                          
     Age                    0.005    −0.104--0.113     0.920   −0.016   −0.102--0.070    0.711
     Sex                    0.014    −0.011--0.395     0.226   −0.027   −0.078--0.025    0.299
     BMI                    0.023    −0.106--0.152     0.683   −0.009   −0.162--0.144    0.903
     Duration of diabetes   −0.093   −0.345--0.159     0.402   0.015    −0.112--0.142    0.807
     Study duration         −0.001   −0.012--0.010     0.789   0.010    −0.006--0.025    0.201
     Baseline HbA1c         0.460    −1.099--2.019     0.515   0.320    −0.535--1.175    0.454
     Baseline weight        −0.007   −0.058--0.044     0.762   /        /                /
     HbA1c change           /        /                 /       0.020    −0.698--0.739    0.954
  GLP-1RA                                                                                
   HbA1c change                                                                          
    Total group                                                                          
     Age                    0.050    −0.033--0.134     0.197   −0.033   −0.121--0.054    0.442
     Sex                    0.005    −0.011--0.020     0.492   0.011    −0.003--0.025    0.112
     BMI                    0.031    −0.065--0.127     0.467   −0.009   −0.094--0.077    0.840
     Duration of diabetes   0.012    −0.068--0.092     0.735   −0.001   −0.044--0.041    0.948
     Study duration         0.006    −0.039--0.050     0.771   0.004    0.001--0.007     0.023
     Baseline HbA1c         0.712    −0.252--1.676     0.124   0.168    −0.129--0.464    0.258
     Baseline weight        0.012    −0.018--0.041     0.390   /        /                /
     Weight change          0.273    −0.298--0.844     0.295   0.023    −0.089--0.135    0.675
  Weight change                                                                          
    Total group                                                                          
     Age                    −0.003   −0.144--0.137     0.955   0.039    −0.211--0.289    0.753
     Sex                    −0.005   −0.031--0.020     0.634   0.024    −0.023--0.072    0.302
     BMI                    0.013    −0.200--0.227     0.886   −0.173   −0.413--0.067    0.152
     Duration of diabetes   0.021    −0.144--0.186     0.771   0.091    −0.048--0.231    0.190
     Study duration         −0.023   −0.083--0.037     0.395   −0.001   −0.016--0.013    0.866
     Baseline HbA1c         1.879    −0.065--3.824     0.056   0.171    −0.975--1.318    0.762
     Baseline weight        −0.003   −0.069--0.064     0.925   −0.032   −0.106--0.042    0.381
     HbA1c change           0.135    −1.490--1.760     0.850   −0.268   −2.021--1.486    0.757

Data are given as median values with the interquartile range in parentheses. *P* values indicated the significance of the comparisons between Asia and Caucasian. *CI*: Confidence interval; SU: Sulfonylurea; BMI: Body mass index; HbA1c: Glycosylated hemoglobin; MET: Metformin; AGI: Alpha glucosidase inhibitors; TZD: Thiazolidinediones; DPP-4i: Dipeptidyl peptidase-4 inhibitors; SGLT2i: Sodium-glucose cotransporter 2 inhibitors; GLP-1RA: Glucagon-like peptide-1 analogs; /: No reported data.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

With the aim of comparisons between Asian and Caucasian population of the placebo effect, this meta-analysis indicated that the overall difference of the placebo effect in HbA1c changes from baseline was not significant, and the difference of the placebo effect in body weight changes from baseline between the two populations was neither significant in the seven kinds of antidiabetic treatments in T2DM. However, it is clear that there was a reduction of HbA1c and body weight due to placebo in each population. These data were based on a large dataset of placebo treatment including 63 studies in Asians and 262 studies in Caucasians. Moreover, placebo effect on HbA1c change or body weight change was not associated with baseline age, gender, BMI, baseline HbA1c, duration of diabetes, and study duration both in Asians and Caucasians.

The term "\'placebo effect" was first introduced by Graves in 1920.\[[@ref23]\] A placebo treatment may be administered through ingestion, injection, inhalation, insertion into a body cavity, or topical application. Placebo effect in T2DM might be associated with the optimal dietary treatment as well as physical activity and exercise for the glucose control and body weight control, besides medication therapy. Some evidence indicated that the dietary treatment for the glucose control might reduce HbA1c by 0.12\~0.5% and also associated with weight change by −0.84\~1.39 kg.\[[@ref24][@ref25][@ref26]\] Physical activity and exercise were also suggested to improve the glucose control in people with T2DM with an average decrease in HbA1c by 0.4\~0.6%.\[[@ref3][@ref4][@ref5]\] All the above may contribute to the placebo effect on glucose control and body weight control. In this meta-analysis, we summarized the exact placebo effect in Caucasian population as well as in Asian population with different treatments for T2DM.

So far, mechanisms that underlie placebo effect are still not clearly understood. As Shapiro *et al*. indicated,\[[@ref6]\] the reasons might fall within one of the three general categories. First, patient variables might be associated with placebo effect, including the attitude toward the physician, the treatment, and the illness, as well as including the levels of anxiety and expectation. However, in this meta-analysis, we could not collect these data from published trials to make further comparisons. Second, the physician variables may be another factor, including the doctor\'s credibility, enthusiasm, authority, empathy, and sympathy, which was also lack of evidence in this study. Third, there might be associated with situational variables, including the location and form of treatment. However, in this study, we compared placebo effect in glucose control and body weight change between Caucasian and Asian population in all the seven kinds of antidiabetic treatments but found no significant difference. Other possible reasons for placebo effect, as indicated by Gowdey\[[@ref2]\] in his review of placebo pharmacology, the influence of expectations might play a role, which could not be confirmed in our study because of no evidence. Besides medication therapy, mechanisms for placebo effect in T2DM might be associated with the optimal dietary approach as well as physical activity to control hyperglycemia in T2DM.\[[@ref2]\] Several reviews and meta-analyses\[[@ref3][@ref4][@ref24]\] indicated that diet and exercise could produce significant improvements in glucose control in people with T2DM. The difference of diet approach between Asian and Caucasian population was reported as the different composition of diet; however, with the rapid development of Asian, the western diet became more and more popular in Asian countries and the difference became smaller and smaller. The difference of physical activity between the two ethnicities was seldom reported and studied; therefore, all the above possible causes or mechanisms that might be associated with the placebo effect in T2DM treatments may not be significantly different between Caucasian and Asian population.

In a recently reported review, Kaptchuk and Miller\[[@ref7]\] suggested that the therapeutic benefits associated with placebo effects did not alter the pathophysiology of diseases beyond their symptomatic manifestations. The observation from our mate-analysis supported the above conclusion. Ulteriorly, we proposed that the placebo effect in HbA1c changes and body weight changes of anti-diabetes treatment were comparable between Caucasians and Asians although there were evidence indicating that the pathophysiology of insulin secretion and insulin resistance was not the same between the two ethnicities.\[[@ref9][@ref14]\] What\'s more, meta-regression analysis from our study also indicated that the placebo effect on HbA1c changes as well as on weight changes from baseline was not associated with baseline factors although the baseline BMI levels were significantly lower in Asians than that in Caucasians.

Certainly, as a meta-analysis, our meta-analysis has some limitations that we will better list here. First, the inclusion criteria and the baseline characteristics such as age, BMI, and duration of diabetes were different across studies, which caused a high level of heterogeneity. However, with the aim of comparisons between Asian and Caucasian population of the placebo effect, we used the random-effect model for analysis when the level of heterogeneity was high and also performed sensitivity analysis. We had also made meta-regression analysis to find if the baseline characteristics were the associated factors. Second, the data on placebo effects on glucose control or body weight control in each trial were used as the parameters in this meta-analysis, but not the pooled, patient-level data, which should be more useful to make a conclusion. However, these data are seldom available because most trials are sponsored by the industry. Therefore, we used the parameters in each trial as surrogates. Third, since no studies of Asian population in SU and MET treatments when we made comparisons of the placebo effect on HbA1c and body weight changes from baseline, it is concerned lack of evidence for comparing the Asian and Caucasian patients in those categories. Moreover, publication bias may also have effects on the results of placebo effects in this meta-analysis; however, a funnel plot assessment was carried out to minimize the risk of publication bias.

In a word, our results from this meta-analysis should be interpreted cautiously. The overall difference of the placebo effect on HbA1c changes as well as on body weight changes was not significant between Asian and Caucasian T2DM patients, but it is clear that there was a reduction of HbA1c and body weight due to placebo in each population. The placebo effect was not associated with baseline age, gender, baseline BMI, baseline HbA1c, duration of diabetes, or study duration.

*Supplementary information is linked to the online version of the paper on the Chinese Medical Journal website*.
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